

## Appendix A

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of

PEPYS

Group Art Unit: 1617

Application No.: 09/737,544

Confirmation No.: 1521

Filed: December 18, 2000

Examiner: Shengjun WANG

Title: TREATMENT AND PREVENTION OF TISSUE DAMAGE

**DECLARATION BY PROFESSOR MARK B. PEPYS**  
**PURSUANT TO 37 C.F.R. §1.132**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Mark B. Pepys, hereby declare as follows:

- (1) I am Professor of Medicine and Head, Department of Medicine, Hampstead Campus, Royal Free and University College Medical School, London, U.K. Further details of my educational qualifications and a list of publications are set out on the attached curriculum vitae (see Appendix A).
- (2) I have worked in the field of chemical, biological, and clinical investigation of C-reactive protein (CRP) for 30 years.
- (3) I am the sole inventor of U.S. Patent Application No. 09/737,544, entitled "Treatment and Prevention of Tissue Damage" ("the '544 application").
- (4) I have invented a method for selecting a pharmaceutical for treating or preventing CRP-mediated tissue damage in a subject comprising identifying and selecting a compound that inhibits the binding of CRP to an autologous or extrinsic ligand thereof, and a method for treating or preventing C-reactive protein (CRP)-mediated tissue damage comprising administering to a subject in need thereof an effective amount of a compound capable of inhibiting the binding of CRP to an

autologous or extrinsic ligand thereof. Original claims 1-25 and 39-48 of the '544 application that were elected for examination are directed to embodiments of my invention pertaining to a method for treating or preventing CRP-mediated tissue damage<sup>in</sup> a subject in need thereof comprising administering to the subject an effective amount of phosphocholine or a derivative thereof that inhibits the binding of CRP to an autologous or extrinsic ligand thereof.

MBP  
28/7/06

(4) I have read and am familiar with the official action issued by the U.S. Patent and Trademark Office and dated September 2, 2005, in connection with the '544 application.

(5) I make this declaration in response to the official action issued September 2, 2005, in which claim 1 was rejected under 35 U.S.C. §112, first paragraph, because the specification is considered to enable one of skill in the art to treat atherosclerosis, but is not considered to provide enablement for preventing atherosclerosis or for treating or preventing tissue damage in general.

(6) The examiner alleges that the term "tissue damaging condition" as used in the application includes all disorders, and argues that the specification is inadequate because it does not teach a method for treating and/or preventing all disorders. I strongly disagree with the examiner's allegation that the term "tissue damaging condition" as used in the '544 application includes all disorders. As amended by the response submitted herewith, claim 1 identifies a selected set of conditions associated with tissue damage accompanied by an elevated level of CRP, for which the claimed method will operate successfully to treat or prevent CRP-mediated tissue damage. In particular, claim 1 clearly specifies that the tissue damage that is treated or prevented by the claimed method is associated with a condition selected from the group consisting of an infection, an allergic complication of infection, an inflammatory disease, ischemic or other necrosis, traumatic tissue damage and malignant neoplasia. The application provides a sound and compelling scientific basis for the breadth of the present claims. All of the information needed by a person of skill in the art to practice the claimed method successfully may be found in the application.

(7) As discussed in the '544 application, CRP-mediated tissue damage that can be treated and/or prevented successfully by the claimed invention includes the tissue damage associated with heart attacks and strokes. Complement mediated inflammation exacerbates the tissue injury of ischemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. The experimental results described herein further demonstrate the operability of the claimed invention, and are additional evidence that a person of skill in the art can practice the claimed invention successfully without having to perform undue experimentation.

(8) I have previously shown that human C-reactive protein (CRP), the classical acute phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation respectively. Rat CRP does not activate rat complement whereas human CRP activates both rat and human complement, and administration of human CRP to rats is thus considered to be an excellent model for actions of endogenous human CRP. Here I describe results obtained upon administering a phosphocholine derivative 1,6-bis(phosphocholine)-hexane, referred to as bis(PC)-H that binds to CRP and inhibits the binding of CRP to its ligands, to rats undergoing acute myocardial infarction. The administration of bis(PC)-H completely abrogates the greatly increased infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction. Other therapeutic applications of the method of administering a phosphocholine derivative that binds to CRP and inhibits the binding of CRP to its ligands include neuroprotection in stroke, and the many other inflammatory, infective and tissue damaging conditions characterized by increased CRP production, in which binding of CRP to ligands exposed in damaged cells may lead to complement mediated exacerbation of tissue injury.

(9) **Methods**

**Reagents and assays.** Human CRP was isolated from malignant ascites fluid as described previously. Human CRP was assayed by the Roche and Dade-Behring methods, and by electroimmunoassay. Rat CRP and C3 were measured by electroimmunoassay. Calcium dependent binding of  $^{125}\text{I}$ -labelled CRP to pneumococcal C-polysaccharide (Statens Serum Institut, Copenhagen, Denmark) and modified human low density lipoprotein, which were covalently immobilized on Corning Costar N-hydroxysuccinimide microtitre plates, was compared in the presence and absence of inhibitor compounds. Binding of CRP to phosphoethanolamine-Sepharose was determined as reported previously for SAP. Activation of complement in whole human serum by CRP and C-polysaccharide in the presence and absence of bis(PC)-H was monitored by 2D immunoelectrophoresis with monospecific antiserum to human C3. Binding affinity of CRP for ligands in solution in 0.01M Tris, 0.14M NaCl, 0.002M  $\text{CaCl}_2$ , 0.1%  $\text{NaN}_3$ , pH 8.0 (TC buffer plus azide) was measured at 37°C by isothermal titration calorimetry. Effects of bis(PC)-H on CRP molecules were monitored by chromatography on a Superdex<sup>TM</sup> 200 HR10/30 column in the AKTA<sup>TM</sup> Explorer 100 HPLC system (Amersham Biosciences) eluted with TC buffer, by uranyl acetate negative staining electron microscopy on carbon grids, and by electrospray mass spectrometry.

**Myocardial infarction.** ALZET<sup>®</sup> osmotic mini-pumps, delivering 10  $\mu\text{l/h}$  for 7 d, were implanted subcutaneously in male Wistar rats (200-220 g) 2 d before coronary artery ligation. Groups A and B received TC buffer; group C received 1.0 M bis(PC)-H in TC buffer, providing 1 mmol/kg/day. Coronary artery ligation, or sham-operation, were performed under intraperitoneal anesthesia with 75 mg/kg ketamine, 0.6 mg/kg xylazine and 0.2 mg/kg atropine and post-operative atipamezole 0.5 mg/kg 2 d after pump implantation. Five daily subcutaneous injections of either TC buffer alone (group A) or human CRP at 40 mg/kg/day in TC buffer (groups B and C) were given, starting immediately after recovery from coronary surgery. Echocardiography (10-22 MHz probe, Dynamic Imaging, Livingston, UK), right carotid artery cannulation using a pressure-transducer tipped catheter (1.4F, Millar Instrument Inc, USA) and cardiac

catheterization were performed on day 5 under isofluorane anesthesia. The rats were then bled, hearts excised, cleaned, weighed and frozen. Frozen hearts were cut transversely into 2.5 mm slices and stained with 1% w/v 2,3,5-triphenyl tetrazolium chloride in phosphate buffer. Infarct size was measured by planimetry (MCID image analysis system, Imaging Research Inc.) on formalin fixed glass mounted sections, and confirmed by dissection and weighing. All treatments and measurements were blinded.

#### (10) **Results**

Bolus intravenous or intraperitoneal injections in mice and rats of up to 1 mmol/kg of bis(PC)-H in physiological saline solution, or continuous infusion at 1 mmol/kg/day for 7 days via subcutaneous osmotic pump, were tolerated without noticeable adverse effects, and inhibited binding of injected human CRP to other ligands and its reactivity in the Roche assay. The plasma half life was ~90 minutes in mice. Continuous infusion of 1 mmol/kg/day of bis(PC)-H in rats completely blocked daily subcutaneous injections of 40 mg/kg of human CRP (~1.74  $\mu$ mol CRP protomer) despite the presence of rat CRP which circulates at 300-500 mg/l, is produced at the rate of ~10  $\mu$ mol protomer/kg/day and bound the drug with  $K_d$  ~ 150 nM.

Clinical treatment with a CRP inhibitor drug would be started immediately on admission to hospital following an acute myocardial infarction, thus preceding the acute phase CRP response, which starts about 6 h after onset of pain and peaks at about 50 h. We therefore initiated infusion of bis(PC)-H before coronary artery ligation in rats, and gave the first of five daily subcutaneous injections of human CRP immediately after recovery from surgery, closely replicating the initial dynamics of the endogenous human CRP response. Administration of human CRP was associated with increased mortality compared to vehicle only controls. In contrast there were no deaths among the rats receiving bis(PC)-H in addition to CRP (Table 1) (Fisher's exact test for comparison of mortality in all groups,  $P=0.08$ ). Infarct size on day 5 was substantially larger in the rats treated with CRP (unpaired t-test,  $P=0.0001$ ), but in rats receiving bis(PC)-H as well as CRP, infarct size was the same as in the vehicle only controls (Table 1). Electro- and echocardiographic indices of

cardiac function on day 5 were consistent with the larger infarcts in the CRP treated rats and with the protective effect of bis(PC)-H (Table 1).


At bleed out on day 5, 24 h after the last dose of human CRP, the mean (SD) serum human CRP concentration in the CRP treated group was 16.7 (10.6) mg/l but human CRP was detectable in the sera of only 4 of the 11 CRP treated rats receiving bis(PC)-H, and at much lower concentration, mean (SD) 3.3 (1.5) mg/l, none of which was detectable by the Roche assay. Continuous infusion of bis(PC)-H thus caused accelerated clearance of human CRP as well as blocking its function.

**Table 1. Enhancement of myocardial infarct size and cardiac dysfunction by human CRP is completely inhibited by 1,6-bis(phosphocholine)-hexane (bis(PC)-H) treatment**

Group (n), treatment	Sham operated	Coronary artery ligation			P values		
	(5), none	A (12), vehicle	B (15), CRP	C (11), CRP + bis(PC)-H	A vs B	A vs C	B vs C
Infarct size (% p)	0	17.0 (3.8)	24.8 (3.3)	18.6 (3.8)	0.0001	0.32	0.0002
Infarct size (% w)	0	17.7 (4.7)	29.5 (5.7)	18.4 (3.7)	0.0001	0.68	0.0001
ST voltage ( $\mu$ V)	-44.8 (24.1)	14.9 (82.3)	95.0 (61.8)*	16.2 (74.3)	0.006	0.97	0.008
Elevated ST, n (%)	0	7 (58.3)	14 (100)*	7 (63.6)	0.007	1.00	0.06
Ejection fraction %	72.67 (3.91)	37.41 (15.95)	28.75 (14.82)	38.40 (11.47)	0.16	0.87	0.08
LVEDP (mm Hg)	4.4 (1.8)	8.8 (4.1)	12.9 (3.8)	4.2 (6.3)	0.01	0.05	0.0002
LVEDD (mm)	6.54 (0.24)	7.43 (0.87)	8.06 (0.74)	7.19 (1.08)	0.05	0.56	0.02
LVESD (mm)	3.1 (0.51)	5.94 (1.39)	6.70 (1.21)	5.60 (1.16)	0.14	0.53	0.03


Values shown are mean (SD). P values are from unpaired t-tests. Infarct size on day 5, % of left ventricle measured by planimetry (p) and by weight (w); ST, ST segment of the electrocardiogram; LVEDP, left ventricular end diastolic pressure; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; \*, n = 14 for these measurements

(11) I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and may jeopardize the validity of the application or any patent issued thereon.



---

MARK B. PEPYS



---

Date



## Appendix B

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of

PEPYS

Group Art Unit: 1617

Application No.: 09/737,544

Confirmation No.: 1521

Filed: December 18, 2000

Examiner: Shengjun WANG

Title: TREATMENT AND PREVENTION OF TISSUE DAMAGE

**KATZ DECLARATION BY PROFESSOR MARK B. PEPYS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Mark B. Pepys, hereby declare as follows:

(1) I am Professor of Medicine and Head, Department of Medicine, Hampstead Campus, Royal Free and University College Medical School, London, U.K., and have worked in the field of chemical, biological, and clinical investigation of C-reactive protein (CRP) for 30 years.

(2) I am the sole inventor of U.S. Patent Application No. 09/737,544, entitled "Treatment and Prevention of Tissue Damage" ("the '544 application").

(3) I have invented a method for selecting a pharmaceutical for treating or preventing CRP-mediated tissue damage in a subject comprising identifying and selecting a compound that inhibits the binding of CRP to an autologous or extrinsic ligand thereof, and a method for treating or preventing C-reactive protein (CRP)-mediated tissue damage comprising administering to a subject in need thereof an effective amount of a compound capable of inhibiting the binding of CRP to an autologous or extrinsic ligand thereof. Original claims 1-25 and 39-48 of the '544 application that were elected for examination are directed to embodiments of my invention pertaining to a method for treating or preventing CRP-mediated tissue

damage a subject in need thereof comprising administering to the subject an effective amount of phosphocholine or a derivative thereof that inhibits the binding of CRP to an autologous or extrinsic ligand thereof.

(4) I have read and am familiar with the official action issued by the U.S. Patent and Trademark Office and dated September 2, 2005, in connection with the '544 application.

(5) I make this declaration in response to the official action issued September 2, 2005, in which claims 1-25 and 42-56 were rejected under 35 U.S.C. §103(a), because the claimed invention allegedly would have been obvious to a person of ordinary skill in the art at the time the invention was made, in view of Bhakdi et al. (Arterioscler. Thromb. Vasc. Biol., 1999, 19:2348-2354), in view of Griselli et al. (J. Exp. Med., December 20, 1999, 190(12): 1733-1739), further in view of Yedgar et al. (U.S. Patent No. 5,064,817) and Wissner et al. (U.S. Patent No. 4,640,913).

(6) I have reviewed the above-identified references cited by the examiner, *i.e.*, Bhakdi et al. (1999), Griselli et al. (1999), Yedgar et al. (U.S. Patent No. 5,064,817) and Wissner et al. (U.S. Patent No. 4,640,913).

(7) The Griselli et al. publication, of which I am a co-author, relates to the invention that is disclosed in the '544 application, and describes experimental results that are disclosed in the '544 application. For example, Figures 1 and 2 and Tables 1 and 2 of the Griselli et al. reference are identical to Figures 1 and 2 and Tables 2 and 3 of the '544 application.


(8) Pursuant to 37 C.F.R. §1.132, I hereby declare that I am the sole inventor of the subject matter disclosed in the Griselli et al. publication. The other authors of the publication, Massimo Griselli, Jeffrey Herbert, Winston L. Hutchinson, Kenneth M. Taylor, Muhammed Sohail, and Thomas Krausz, worked under my direction and supervision and were not co-inventors. *See In re Katz*, 215 U.S.P.Q. 14 (CCPA 1982).

At the time the work reported in the Griselli et al. article was performed, Massimo Griselli was an M.S. (Surgery) student, and I was his supervisor; Jeffrey Herbert was a clinical scientist (a member of staff in the department); Winston Hutchinson was a Principle Research Fellow (also member of staff in the dept); Professor Kenneth Taylor was joint supervisor of Massimo Griselli (Dept. of Surgery); and Muhammed Sohail and Thomas Krausz (both of whom are histopathologists) were acting as collaborators.

The work reported in the Griselli et al. reference was entirely my idea, including the experimental approach, all aspects of the experiments and the writing of the manuscript. I organized a suitable team including members of <sup>my</sup> his own laboratory and others with the necessary expertise. Thus I enlisted the collaboration of K. Taylor, the Professor of Cardiac Surgery, who provided M. Griselli, a trainee surgeon, to do the rat surgery, and T. Krausz, the Professor of Histopathology, who provided M. Sohail, a trainee histopathologist, to do the histology. The other authors thus made essentially technical contributions, albeit at a high level, rather than intellectual contributions to the work.

MBP.  
28/3/06

(9) I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and may jeopardize the validity of the application or any patent issued thereon.



MARK B. PEPYS



Date

## Appendix C

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of

PEPYS

Group Art Unit: 1617

Application No.: 09/737,544

Confirmation No.: 1521

Filed: December 18, 2000

Examiner: Shengjun WANG

Title: TREATMENT AND PREVENTION OF TISSUE DAMAGE

**DECLARATION BY PROFESSOR MARK B. PEPYS**  
**PURSUANT TO 37 C.F.R. §1.131**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, Mark B. Pepys, hereby declare as follows:

(1) I am Professor of Medicine and Head, Department of Medicine, Hampstead Campus, Royal Free and University College Medical School, London, U.K., and have worked in the field of chemical, biological, and clinical investigation of C-reactive protein (CRP) for 30 years.

(2) I am the sole inventor of U.S. Patent Application No. 09/737,544, entitled "Treatment and Prevention of Tissue Damage" ("the '544 application").

(3) I have invented a method for selecting a pharmaceutical for treating or preventing CRP-mediated tissue damage in a subject comprising identifying and selecting a compound that inhibits the binding of CRP to an autologous or extrinsic ligand thereof, and a method for treating or preventing C-reactive protein (CRP)-mediated tissue damage comprising administering to a subject in need thereof an effective amount of a compound capable of inhibiting the binding of CRP to an autologous or extrinsic ligand thereof. Original claims 1-25 and 39-48 of the '544 application that were elected for examination are directed to embodiments of my

invention pertaining to a method for treating or preventing CRP-mediated tissue damage in a subject in need thereof comprising administering to the subject an effective amount of phosphocholine or a derivative thereof that inhibits the binding of CRP to an autologous or extrinsic ligand thereof. Prior to my present invention, it was not known that CRP is capable of mediating tissue damage, or that a compound that inhibits the binding of CRP to an autologous or extrinsic ligand thereof such as phosphocholine or a derivative thereof could be administered to a subject to successfully treat or prevent CRP-mediated tissue damage.

(4) I have read and am familiar with the official action issued by the U.S. Patent and Trademark Office dated September 2, 2005, in connection with the '544 application.

(5) I make this declaration in response to the official action issued September 2, 2005, in which claims 1-25 and 42-56 were rejected under 35 U.S.C. §103(a), because the claimed invention allegedly would have been obvious to a person of ordinary skill in the art at the time the invention was made, in view of Yeh et al. (U.S. Patent No. 6,764,826), in view of Bhakdi et al. (Arterioscler. Thromb. Vasc. Biol., 1999, 19:2348-2354), and further in view of Yedgar et al. (U.S. Patent No. 5,064,817) and Wissner et al. (U.S. Patent No. 4,640,913).

(6) I have reviewed the above-identified references cited by the examiner, *i.e.*, Yeh et al. (U.S. Patent No. 6,764,826), Bhakdi et al. (1999), Yedgar et al. (U.S. Patent No. 5,064,817) and Wissner et al. (U.S. Patent No. 4,640,913).


(7) The effective date of U.S. Patent No. 6,764,826 of Yeh et al., which is cited as the primary reference in the rejection of claims 1-25 and 42-56 under 35 U.S.C. §103(a), is June 8, 2000, which is the date that the patent is effective as a 102(e) reference (*see* 37 C.F.R. §1.131(a)(1)). The effective date of U.S. Patent No. 6,764,826 of Yeh et al. is therefore less than a year prior to the filing date of the present application, which was filed on December 18, 2000.

(8) The six claims of U.S. Patent No. 6,764,826 of Yeh et al. are all directed to an in vitro method for screening for modulators of human C-reactive protein. The claims of U.S. Patent No. 6,764,826 of Yeh et al. are therefore directed to subject matter that is different from the subject matter of the rejected claims, which are directed to a therapeutic method for treating or preventing CRP-mediated tissue damage in a subject.

(9) I hereby declare that I invented the subject matter of the rejected claims prior to the effective date of U.S. Patent No. 6,764,826 of Yeh et al., which is June 8, 2000. Evidence of my prior invention is found in Griselli et al., a scientific article published in the Journal of Experimental Medicine (vol. 190 (sec. 12), pages 1733-1739) with a publication date of December 20, 1999. As I declared in a declaration under 37 C.F.R. §1.132 submitted herewith, I am the sole inventor of the subject matter disclosed Griselli et al., as the other authors of the publication worked under my direction and supervision and were not co-inventors. Griselli et al. provides the first publicly disclosed demonstration that CRP is capable of mediating tissue damage in a mammal. The materials and methods, experimental results shown in Figures 1-2 and Tables I-II, and the discussion of the significance of these results with respect to clinical benefits provided by to patients treating or preventing CRP-mediated tissue damage associated with traumatic, infectious, inflammatory, and neoplastic tissue-damaging conditions, described on pages 1734-1737 of Griselli et al., are identical to materials and methods, experimental results, and discussion, found on pages 25-34, 36, and 37 of the application filed on December 18, 2000. After the publication of Griselli et al. on December 20, 1999, the inventor has worked diligently on the claimed invention, as evidenced by the filing of the present application, the publication of Gill et al. in 2004 (Journal of Cerebral Blood Flow and Metabolism, 24(11:1214-1218)), which describes experimental results demonstrating that CRP-mediate tissue damage associated with cerebral infarct, and the award to the inventor in 2004 by the U.S. National Institutes of Health of a research grant of \$861,200 over 4 years entitled "*Targeting C-reactive protein in atherothrombotic disease.*"



(10) I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and may jeopardize the validity of the application or any patent issued thereon.



---

MARK B. PEPYS



---

Date

## Appendix D

**MARK BRIAN PEPYS**

**CURRICULUM VITAE**

**Name** MARK BRIAN PEPYS

**Address** 22 Wildwood Road, London NW11

**Date of birth** 18th September, 1944

**Present appointment**

**Date of  
Appointment**

Professor of Medicine and Head, Department of Medicine,  
Hampstead Campus, Royal Free and University College  
Medical School, University College London

01/10/99

## MARK BRIAN PEPYS

### University Education

Trinity College, Cambridge	1962-1965
University College Hospital Medical School	1965-1968

### Degrees

B.A. (Hons.) (Cantab.)			1965
Natural Sciences Tripos:	Part I	Class I	
	Part II	Class I	
M.B., B.Chir. (Cantab.)			1968
M.A. (Cantab.)			1970
M.R.C.P. (U.K.)			1970
Ph.D. (Cantab.)	<i>"Role of complement in induction of the allergic response"</i>		1974
F.R.C.P.			1981
M.R.C.Path.			1981
M.D. (Cantab.)	<i>"Clinical and experimental studies of C-reactive protein and amyloid P component"</i>		1982
F.R.C.Path.			1991
F.R.S.			1998
F.Med.Sci.			1998

### Academic distinctions

State Scholarship	1961
-------------------	------

### *Trinity College, Cambridge:*

Open Exhibition in Natural Sciences	1961
Preliminary Examination for Natural Sciences Tripos, Class I	1963
Preliminary Examination Prize	1963
Natural Sciences Tripos, Part I, Class I	1964
Senior Scholarship	1964
Natural Sciences Tripos, Part II (Pathology), Class I	1965
Tripos Examination Prize	1965
Research Scholarship	1970
Fellowship (Title A)	1973-1979

## MARK BRIAN PEPYS

### *University College Hospital Medical School:*

Filliter Entrance Scholarship in Pathology and Microbiology	1965
Trotter Medal for Clinical Surgery	1966
Alexander Bruce Gold Medal for Surgical Pathology	1967
Filliter Exhibition in Pathology and Microbiology	1967
Fellowes Gold Medal for Clinical Medicine	1967
Sir William Gowers Prize for Clinical Medicine	1967
Liston Gold Medal for Clinical Surgery	1967
Atchison Scholarship for "Clinical and Academic Attainment"	1968-1969

### *Royal College of Physicians:*

Goulstonian lecturer	
"C-reactive protein, amyloidosis and the acute phase response"	1982
Lumleian lecturer	
"C-reactive protein and amyloidosis: from proteins to drugs?"	1998
Moxon Trust Medal	1999

### *Royal College of Pathologists:*

Kohn lecturer	
"Serum amyloid P component: molecular interactions and clinical applications"	1991

### *Royal College of Surgeons of England:*

Sir Arthur Sims Commonwealth Travelling Professorship	1991
---	------

### *Royal Society of London:*

Fellow	1998
--------	------

### *Academy of Medical Sciences:*

Founder Fellow	1998
----------------	------

### *Renal Association:*

Chandos lecturer	
"Prognostic and pathogenetic significance of C-reactive protein"	2000

## MARK BRIAN PEPYS

### ***British Society for Rheumatology:***

Heberden medallist and orator

*"Pentraxins in rheumatology: physiology, pathology  
and new drugs"*

2002

### ***University College London:***

Fellow

2003

### ***American Society of Nephrology:***

State of the Art lecturer

*"Recent advances in systemic amyloidosis"*

2003

### ***Israel Society for Rheumatology:***

Gerald Loewi Memorial lecturer

*"Amyloidosis and C-reactive protein: from old  
molecules to new drugs"*

2004

### ***Imperial College Faculty of Medicine:***

Fellow

2004

## **Membership of Scientific and Medical Societies**

Fellow of the Royal Society

Fellow of the Royal College of Physicians, London

Fellow of the Royal College of Pathologists

Founder Fellow of the Academy of Medical Sciences

Honorary Member of the Association of Physicians

Member

Medical Research Society

British Society for Immunology

British Society for Allergy and Clinical Immunology

International Society for Amyloidosis

Antibody Club

Biochemical Society

British Society for Rheumatology

Molecular Medicine Society (Fellow)

Society for Neuroscience

American Association for the Advancement of Science

British Association

## MARK BRIAN PEPYS

### Membership of Academic Committees

University Grants Committee Equipment Sub-Committee	1989
Medical Research Council Systems Board Grants Committee B	1986-1990
Royal College of Physicians Specialist Committee on Clinical Immunology and Allergy	1988-1991
Royal Society Grants Committee F	1998-2001
Royal Society Sectional Committee 10	2001-2003
Medical Research Council Molecular and Cell Medicine Board	2000-2004
Royal Society Council	2003-2005
Academy of Medical Sciences Council	2004-2006

### Membership of Editorial Boards

Journal of Immunological Methods	1975-1982
Clinical and Experimental Immunology	1980-1997
Clinical Allergy	1984-1988
Biochemical Journal, Editorial Adviser	1991-1998
Amyloid: Journal of Protein Folding Disorders	1994-

### Previous appointments

House Physician to Medical Unit, University College Hospital, (Professor Lord Rosenheim, Professor C.E. Dent, FRS and Dr C.J. Dickinson)	1968-1969
House Surgeon to Surgical Unit, University College Hospital	1969
Senior House Officer to Dr D.K. Peters, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1969-1970
Research Assistant to Dr D.K. Peters, Honorary Medical Registrar, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1970
M.R.C. Junior Research Fellowship, Immunology Division (Professor R.R.A. Coombs, FRS), Department of Pathology, University of Cambridge	1970-1973
Research Scholar, Trinity College, Cambridge	1970-1973
Fellow, Trinity College, Cambridge	1973-1979
Medical Registrar to Professor C.C. Booth, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1973-1974



## MARK BRIAN PEPYS

### Previous appointments (cont)

Assistant Lecturer in Medicine, Honorary Senior Registrar to Professor C.C. Booth, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1974-1976
Senior Lecturer and Head of Immunology, Honorary Consultant, Royal Free Hospital School of Medicine	1976-1977
Senior Lecturer in Medicine, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1977-1980
Consultant Physician, Hammersmith Hospital, London	1977-1999
Reader in Immunological Medicine, Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital	1980-1984
Group Leader, MRC Acute Phase Protein Research Group	1983-1988
Professor of Immunological Medicine, Department of Medicine, Royal Postgraduate Medical School, London	1984-1999
Assistant Director (Research), Department of Medicine, Royal Postgraduate Medical School, London	1987-1989
Research Coordinator to Hammersmith and Queen Charlotte's Special Health Authority	1988-1995

### Research grants awarded

1975	Medical Research Council. <i>"Role of lymphocytes and complement in immunological function of the intestine"</i> £40,000 over 4 years
1977	Medical Research Council. <i>"Identification and absolute enumeration of lymphocyte populations in whole blood and tissue sections"</i> £33,000 over 3 years
1977	Medical Research Council. <i>"Role of complement in the induction of antibody formation in human and murine systems"</i> £33,000 over 3 years
1977	Medical Research Council. <i>"Immunological mechanisms underlying the acute and chronic relapsing forms of experimental allergic neuritis"</i> £34,000 over 3 years (with Professor P.K. Thomas)

## MARK BRIAN PEPYS

### Research grants awarded (cont)

- |      |   |
|------|---|
| 1977 | Wellcome Trust. <i>"Investigation of possible immunological factor in epilepsy"</i><br>£20,000 over 2 years (with Professor G. Ettlinger)   |
| 1978 | Wellcome Trust. <i>"Role of C-reactive protein in immunological responses"</i><br>£25,000 over 3 years  |
| 1978 | National Kidney Research Fund. <i>"C-reactive and amyloid P proteins in renal disease"</i><br>£15,000 over 2 years  |
| 1979 | Medical Research Council. Programme Grant. <i>"Biological and clinical studies of C-reactive protein and serum amyloid P component"</i><br>£240,000 over 5 years  |
| 1979 | Fisons Limited. <i>"Therapeutic trial of absorbable cromone in Crohn's disease"</i><br>£17,000 over 2 years (with Dr V.S. Chadwick)   |
| 1980 | Leukaemia Research Fund. <i>"Characterisation by surface markers and enumeration of leukaemic cells in whole blood using monoclonal antibodies and alkaline phosphatase labelled reagents: a method for routine clinical use"</i><br>£35,000 over 3 years |
| 1981 | Medical Research Council<br>Training Fellowship for Dr I.F. Rowe<br>£30,000 over 3 years  |
| 1981 | Cancer Research Campaign. <i>"Role of the interaction between fibronectin and amyloid P component in cell-substratum interactions of normal and malignant cells"</i><br>£25,000 over 2 years  |
| 1982 | Medical Research Council<br>Training Fellowship for Dr C.R.K. Hind<br>£33,000 over 3 years  |
| 1983 | Medical Research Council. Programme Grant. Renewed for 1984-1989<br>£302,000 over 5 years   |

## MARK BRIAN PEPYS

### Research grants awarded (cont)

- |      |   |
|------|---|
| 1983 | Medical Research Council. Group status awarded and designated as the MRC Acute Phase Protein Research Group<br>£78,315 over 5 years   |
| 1986 | Medical Research Council<br>Training Fellowship for Dr P.N. Hawkins<br>£45,000 over 3 years   |
| 1986 | Medical Research Council. <i>"The three-dimensional structure analysis of pentraxins: biochemical and X-ray studies of serum amyloid P component"</i><br>£52,000 over 3 years (with Dr S.P. Wood and Professor T.L. Blundell)                   |
| 1987 | Medical Research Council. <i>"<math>\beta_2</math>-Microglobulin derived amyloidosis in haemodialysis and CAPD: precursor protein clearance and amyloidogenesis"</i><br>£46,000 over 2 years (with Dr F.W. Ballardie and Professor D.N.S. Kerr) |
| 1987 | Medical Research Council. <i>"Structural studies of amyloid fibril proteins and their precursors"</i><br>£44,000 over 3 years   |
| 1988 | Arthritis and Rheumatism Council. <i>"Molecular, biological and clinical studies of pentraxin-chromatin interactions"</i><br>£52,680 over 3 years   |
| 1989 | Medical Research Council. <i>"Characterisation of amyloid fibril-associated glycosaminoglycans"</i><br>£19,922 over 1 year  |
| 1989 | Wellcome Trust. <i>"Localisation of serum amyloid P component in joints in vivo: mechanisms and significance"</i><br>£96,500 over 2 years   |
| 1989 | Medical Research Council. Programme Grant. <i>"Structural, functional and clinical studies of the pentraxins and amyloidosis"</i><br>Renewed for 1989-1994<br>£532,600 over 5 years   |

## MARK BRIAN PEPYS

### Research grants awarded (cont)

- |      |   |
|------|---|
| 1989 | Medical Research Council. <i>"Three dimensional structure analysis of pentraxins: X-ray studies of ligand binding to serum amyloid P component"</i><br>£87,300 over 3 years (with Professor T.L. Blundell and Dr S.P. Wood) |
| 1989 | Horserace Betting Levy Board. <i>"Development of an equine acute phase protein test for diagnosis"</i><br>£44,830 over 3 years  |
| 1990 | Medical Research Council. <i>"In vivo distribution, clearance and metabolism of C-reactive protein in man in health and disease"</i><br>£100,500 over 3 years (with Dr P.N. Hawkins)  |
| 1991 | Medical Research Council. Supplement to Programme Grant.<br>1990-1994<br>£108,000 over 4 years  |
| 1991 | Medical Research Council. <i>"Characterisation of apoA-I mutations and mechanisms of amyloidogenesis in familial systemic Ostertag-type amyloidosis"</i><br>£75,000 over 2 years (with Dr A.K. Soutar and Dr P.N. Hawkins)  |
| 1991 | The Maurice Wohl Charitable Foundation<br>£90,000 towards building of new laboratories  |
| 1993 | Medical Research Council. <i>"Expression, structure and properties of the human lysozyme variants Thr56 and His67. A new model of amyloidogenesis"</i><br>£90,613 over 2 years (with Dr A.K. Soutar)                        |
| 1993 | Medical Research Council<br>Training Fellowship for Dr L.B. Lovat<br>£82,500 over 3 years   |
| 1994 | Wellcome Trust. <i>"Biomedical applications of mass spectrometry"</i><br>£312,369 (with Dr G.W. Taylor, Professor D.S. Davies and Professor R.I. Lechler)   |

## MARK BRIAN PEPYS

### Research grants awarded (cont)

- 1994 Medical Research Council. Programme Grant. "*Structural, functional and clinical studies of the pentraxins and amyloidosis*"  
Renewed for 1994-1999  
£2,035,148 over 5 years (with Dr P.N. Hawkins)
- 1994 Medical Research Council. "*Structure and ligand binding of serum amyloid P component*"  
£134,858 over 3 years (with Dr S.P. Wood and Dr I.J. Tickle)
- 1995 Arthritis and Rheumatism Council  
Clinical Research Fellowship for Dr M.C.M. Bickerstaff  
£119,717 over 3 years (with Professor M.J. Walport)
- 1996 Medical Research Council. Supplement to Programme Grant  
1996-1999  
£148,584 over 3 years (with Dr P.N. Hawkins)
- 1996 F. Hoffmann-La Roche Ltd. "*Studies of serum amyloid P component in amyloidosis*"  
£302,000 for equipment
- 1996 The Wellcome Trust. University Award for Dr P.N. Hawkins  
"*Diagnostic, pathogenetic and therapeutic studies in amyloidosis*"  
£205,412 over 3 years
- 1996 The Maurice Wohl Charitable Foundation  
£22,000 towards purchase of equipment
- 1997 The Wellcome Trust. "*Ligand recognition and structure-function relationships in human C-reactive protein*"  
£166,030 over 3 years (with Dr S.P. Wood)
- 1997 F. Hoffmann-La Roche Ltd. "*Studies of serum amyloid P component in amyloidosis*"  
£105,000 over 1 year
- 1998 Joint Medical Research Council and Department of Health  
Transmissible Spongiform Encephalopathies Initiative. "*Do scrapie and Creutzfeldt-Jakob disease develop normally in mice with targeted deletion of the serum amyloid P component gene?*"  
£315,482 over 3 years (with Professor J. Collinge, Dr M.E. Bruce and Ms P.A. McBride)

## MARK BRIAN PEPYS

### Research grants awarded (cont)

- |      |  |
|------|--|
| 1998 | Medical Research Council<br>Clinical Training Fellowship for Dr M. Noursadeghi<br>£108,800 over 3 years (with Professor J. Cohen)  |
| 1999 | The Wellcome Trust<br>Research Training Fellowship for Dr J.D. Gillmore<br>£151,974 over 3 years   |
| 1999 | Medical Research Council. Programme Grant. <i>"Pentraxins and amyloidosis: Functions and clinical significance"</i><br>Renewed for 1999-2004<br>£2,362,180 over 5 years (with Professor P.N. Hawkins)  |
| 2000 | British Heart Foundation. <i>"The diagnostic and prognostic significance of inflammation and the possession of certain vascular and inflammatory polymorphisms in coronary in-stent restenosis"</i><br>£131,592 over 2 years (with Dr K.M. Fox and Professor S. Humphries)   |
| 2000 | Medical Research Council, Development Grant<br><i>"Structural analysis of ligand recognition and associated biological roles of pentraxins"</i><br>£227,474 over 3 years (with Professor S.P. Wood)  |
| 2000 | Medical Research Council<br>Clinical Training Fellowship for Dr G.M. Hirschfield<br>£112,753 over 3 years  |
| 2001 | Supplement and extension to Joint Medical Research Council and Department of Health Transmissible Spongiform Encephalopathies Initiative. <i>"Do scrapie and Creutzfeldt-Jakob disease develop normally in mice with targeted deletion of the serum amyloid P component gene?"</i><br>£60,636 over 18 months (with Professor J. Collinge, Dr M.E. Bruce and Ms P.A. McBride) |
| 2002 | The Wolfson Foundation, Equipment Grant<br><i>"Molecules to medicines at the Royal Free"</i><br>£1,500,000 (with Dr J.J. Hsuan)  |
| 2004 | British Heart Foundation<br>PhD Studentship for Ms H. Mikolajek<br>£68,208 over 3 years (with Professor S.P. Wood)   |

**MARK BRIAN PEPYS****Research grants awarded (cont)**

- 2004            Medical Research Council. Programme Grant. *"Pentraxins and amyloidosis: From molecular mechanisms to medicines"*  
Renewed for 2004-2009  
£1,800,016 over 5 years (with Professor P.N. Hawkins)
- 2004            National Institutes of Health  
*"Targeting C-reactive protein in atherothrombotic disease"*  
\$861,200 over 4 years

## PUBLICATIONS

### I. ORIGINAL PAPERS

#### A. *Complement and induction of immunological responses*

1. Pepys, M.B. (1972) Role of complement in induction of the allergic response. *Nature New Biol.*, **237**: 157-159.
2. Janossy, G., Humphrey, J.H., Pepys, M.B. and Greaves, M.F. (1973) Complement independence of stimulation of mouse splenic B lymphocytes by mitogens. *Nature New Biol.*, **245**: 108-112.
3. Pepys, M.B. (1974) Complement-mediated mixed aggregation of murine spleen cells. *Nature*, **249**: 51-53.
4. Feldmann, M. and Pepys, M.B. (1974) Role of C3 in *in vitro* lymphocyte cooperation. *Nature*, **249**: 159-161.
5. Pepys, M.B. and Taussig, M.J. (1974) Complement-independence of tolerance induction. *Eur. J. Immunol.*, **4**: 349-352.
6. Pepys, M.B. (1974) Role of complement in induction of antibody production *in vivo*. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. *J. Exp. Med.*, **140**: 126-145.
7. Pepys, M.B. and Butterworth, A.E. (1974) Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation. *Clin. Exp. Immunol.*, **18**: 273-282.
8. Pepys, M.B. (1975) Studies *in vivo* of cobra factor and murine C3. *Immunology*, **28**: 369-377.
9. Pepys, M.B. and Wilson, D.V. (1975) A new immunoassay for C3. Application of the cell-linked antigen radioactive antibody (CLARA) technique. *J. Immunol. Methods*, **6**: 225-233.
10. Papamichail, M., Gutierrez, C., Embling, P., Johnson, P., Holborow, E.J. and Pepys, M.B. (1975) Complement dependence of localisation of aggregated IgG in germinal centres. *Scand. J. Immunol.*, **4**: 343-347.
11. Pepys, M.B., Bell, A.J. and Rowe, I.F. (1975) Sepharose-C3. I. Preparation and use as an immunosorbent. *Scand. J. Immunol.*, **5**: 75-78.



12. Pepys, M.B., Bell, A.J. and Rowe, I.F. (1975) Sepharose-C3. II. Specific depletion of complement receptor lymphocytes. *Scand. J. Immunol.*, **5**: 79-82.
13. Pepys, M.B. (1976) Role of complement in the induction of immunological responses. *Transplant Rev.*, **32**: 93-120.
14. Pepys, M.B., Wansbrough-Jones, M.H. and Mirjah, D.D. (1976) Suppression of IgA antibody produced by *in vivo* complement depletion. *Clin. Exp. Immunol.*, **23**: 378-381.
15. Pepys, M.B., Mirjah, D.D., Dash, A.C. and Wansbrough-Jones, M.H. (1976) Immunosuppression by cobra factor: distribution, antigen-induced blast transformation and trapping of lymphocytes during *in vivo* complement depletion. *Cell. Immunol.*, **21**: 327-336.
16. Pepys, M.B., Brighton, W.D., Hewitt, B.E., Bryant, D.E.W. and Pepys, J. (1977) Complement in the induction of IgE antibody formation. *Clin. Exp. Immunol.*, **27**: 397-400.
17. Pepys, M.B., Dash, A.C., Fielder, A.H.L. and Mirjah, D.D. (1977) Isolation and study of murine C3. *Immunology*, **33**: 491-499.
18. Papamichail, M. and Pepys, M.B. (1978) Interaction between lymphocytes and fluid phase murine and human C3b. *J. Immunol.*, **120**: 1971.
19. Rumjanek, V.M., Brent, L. and Pepys, M.B. (1978) Cell-mediated immunological responsiveness in mice de complemented with cobra venom factor. *Immunology*, **34**: 1117-1123.
20. Papamichail, M. and Pepys, M.B. (1979) Lymphocyte binding of fluid phase mouse C3b. *Immunology*, **36**: 461-470.
21. Papamichail, M., Tsokos, G., Pepys, M.B., Weyman, C., Belin, J. and Smith, A.D. (1979) Inhibition of complement-dependent rosette formation after lymphocyte incubation with fatty acids. *Immunology*, **38**: 117-122.
22. Jungi, T.W. and Pepys, M.B. (1981) Delayed hypersensitivity reactions to *Listeria monocytogenes* in rats de complemented with cobra factor and in C5-deficient mice. *Immunology*, **43**: 271-279.
23. Vignali, D.A.A., Bickle, Q.D., Taylor, M.G., Tennent, G. and Pepys, M.B. (1988) Comparison of the role of complement in immunity to *Schistosoma mansoni* in rats and mice. *Immunology*, **63**: 55-61.
24. Kopf, M., Herren, S., Wiles, M.V., Pepys, M.B. and Kosco-Vilbois, M.H. (1998) Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. *J. Exp. Med.*, **188**: 1895-1906.

## **B. C-reactive protein, amyloid P component and the acute phase response**

### *Experimental studies*

1. Pepys, M.B., Dash, A.C., Munn, E.A., Feinstein, A., Skinner, M., Cohen, A.S., Gewurz, H., Osmand, A.P. and Painter, R.H. (1977) Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. *Lancet*, **i**: 1029-1031.
2. Pepys, M.B., Dash, A.C. and Ashley, M.J. (1977) Isolation of C-reactive protein by affinity chromatography. *Clin. Exp. Immunol.*, **30**: 32-37.
3. Pepys, M.B., Dash, A.C., Fletcher, T.C., Richardson, N., Munn, E.A. and Feinstein, A. (1978) Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. *Nature*, **273**: 168-170.
4. Pepys, M.B., Baltz, M., Gomer, K., Davies, A.J.S. and Doenhoff, M. (1979) Serum amyloid P-component is an acute-phase reactant in the mouse. *Nature*, **278**: 259-261.
5. Pepys, M.B. (1979) Isolation of serum amyloid P-component (protein SAP) in the mouse. *Immunology*, **37**: 637-641.
6. Pepys, M.B., Baltz, M.L., Musallam, R. and Doenhoff, M.J. (1980) Serum protein concentrations during *Schistosoma mansoni* infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP). *Immunology*, **39**: 249-254.
7. Pepys, M.B., Baltz, M.L., Musallam, R., Doenhoff, M.J., Gomer, K. and Davies, A.J.S. (1980) Role of T lymphocytes and polymorphs in induction of acute phase production of murine C3. *J. Immunol.*, **124**: 1535.
8. Pepys, M.B. and Rogers, S.L. (1980) Complement-independence of the acute-phase production of serum amyloid P-component (SAP) in mice. *Brit. J. Exp. Pathol.*, **61**: 156-159.
9. Pepys, M.B., Becker, G.J., Dyck, R.F., McCraw, A., Hilgard, P., Merton, R.E. and Thomas, D.P. (1980) Studies of human serum amyloid P-component (SAP) in relation to coagulation. *Clin. Chim. Acta*, **105**: 83-91.
10. Dyck, R.F., Lockwood, C.M., Kershaw, M., McHugh, N., Duance, V.C., Baltz, M.L. and Pepys M.B. (1980) Amyloid P-component is a constituent of normal human glomerular basement membrane. *J. Exp. Med.*, **152**: 1162-1174.
11. Hutchcraft, C.L., Gewurz, H., Hansen, B., Dyck, R.F. and Pepys, M.B. (1981) Agglutination of complement-coated erythrocytes by serum amyloid P-component. *J. Immunol.*, **126**: 1217-1219.

12. de Beer, F.C., Baltz, M.L., Holford, S., Feinstein, A. and Pepys, M.B. (1981) Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. *J. Exp. Med.*, **154**: 1134-1149.
13. White, A., Fletcher, T.C., Pepys, M.B. and Baldo, B.A. (1981) The effect of inflammatory agents on C-reactive protein and serum amyloid P-component levels in plaice (*Pleuronectes platessa* L.) serum. *Comp. Biochem. Physiol.*, **69C**: 325-329.
14. Breathnach, S.M., Melrose, S.M., Bhogal, B., de Beer, F.C., Dyck, R.F., Tennent, G., Black, M.M. and Pepys, M.B. (1981) Amyloid P component is located on elastic fibre microfibrils of normal human tissue. *Nature*, **293**: 652-654.
15. de Beer, F.C., Baltz, M.L., Munn, E.A., Feinstein, A., Taylor, J., Bruton, C., Clamp, J.R. and Pepys, M.B. (1982) Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. *Immunology*, **45**: 55-70.
16. Pepys, M.B., Rogers, S.L. and Evans, D.J. (1982) Role of the acute phase response in the Shwartzman phenomenon. *Clin. Exp. Immunol.*, **47**: 289-295.
17. Baltz, M.L., de Beer, F.C., Feinstein, A. and Pepys, M.B. (1982) Calcium-dependent aggregation of human serum amyloid P component. *Biochim. Biophys. Acta*, **701**: 229-236.
18. de Beer, F.C. and Pepys, M.B. (1982) Isolation of human C-reactive protein and serum amyloid P component. *J. Immunol. Methods*, **50**: 17-31.
19. de Beer, F.C. and Pepys, M.B. (1982) Solid-phase immunoradiometric assay for C-reactive protein using magnetisable cellulose particles. *J. Immunol. Methods*, **50**: 299-308.
20. Pepys, M.B., de Beer, F.C., Milstein, C.P., March, J.F., Feinstein, A., Buttress, N., Clamp, J.R., Taylor, J., Bruton, C. and Fletcher, T.C. (1982) C-reactive protein and serum amyloid P component in the plaice (*Pleuronectes platessa* L.), a marine teleost, are homologous with their human counterparts. *Biochim. Biophys. Acta*, **704**: 123-133.
21. Baltz, M.L., de Beer, F.C., Feinstein, A., Munn, E.A., Milstein, C.P., Fletcher, T.C., March, J.F., Taylor, J., Bruton, C., Clamp, J.R., Davies, A.J.S. and Pepys, M.B. (1982) Phylogenetic aspects of C-reactive protein and related proteins. *Ann. N.Y. Acad. Sci.*, **389**: 49-75.
22. Pepys, M.B., Baltz, M.L., de Beer, F.C., Dyck, R.F., Holford, S., Breathnach, S.M., Black, M.M., Tribe, C.R., Evans, D.J. and Feinstein, A. (1982) Biology of serum amyloid P component. *Ann. N.Y. Acad. Sci.*, **389**: 286-298.

23. Baltz, M.L., Simmons, D., Simpson, W., Gomer, K., Davies, A.J.S. and Pepys, M.B. (1982) The acute phase reaction in experimental infections. Role of the specific host immunological response and different patterns in different acute phase reactants. *Ann. N.Y. Acad. Sci.*, **389**: 427-428.
24. Baltz, M.L., Holford, S., de Beer, F.C., Whaley, K. and Pepys, M.B. (1982) The interaction between human serum amyloid P component (SAP) and fixed complement. *Ann. N.Y. Acad. Sci.*, **389**: 429-430.
25. Taylor, J., Bruton, C., Clamp, J.R., de Beer, F.C., Baltz, M.L. and Pepys, M.B. (1982) Studies of the primary structure of mouse serum amyloid P component (SAP). *Ann. N.Y. Acad. Sci.*, **389**: 471.
26. de Beer, F.C., Soutar, A.K., Baltz, M.L., Trayner, I.M., Feinstein, A. and Pepys, M.B. (1982) Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. *J. Exp. Med.*, **156**: 230-242.
27. de Beer, F.C., Dyck, R.F. and Pepys, M.B. (1982) Solid-phase immunoradiometric assay for serum amyloid A protein using magnetisable cellulose particles. *J. Immunol. Methods*, **54**: 213-221.
28. Rordorf, C., Schnebli, H.P., Baltz, M.L., Tennent, G. and Pepys, M.B. (1982) The acute-phase response in (NZB x NZW)<sub>F1</sub> and MRL/l mice. Contrasting patterns resembling those in human systemic lupus erythematosus and rheumatoid arthritis, respectively. *J. Exp. Med.*, **156**: 1268-1273.
29. de Beer, F.C., Shine, B. and Pepys, M.B. (1982) Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. *Clin. Exp. Immunol.*, **50**: 231-237.
30. White, A., Fletcher, T.C. and Pepys, M.B. (1983) Serum concentrations of C-reactive protein and serum amyloid P component in plaice (*Pleuronectes platessa* L.) in relation to season and injected lipopolysaccharide. *Comp. Biochem. Physiol. B*, **74**: 453-458.
31. Breathnach, S.M., Melrose, S.M., Bhogal, B., de Beer, F.C., Black, M.M. and Pepys, M.B. (1983) Immunohistochemical studies of amyloid P component distribution in normal human skin. *J. Invest. Dermat.*, **80**: 86-90.
32. Dunne, D.W., Hassounah, O., Musallam, R., Lucas, S., Pepys, M.B., Baltz, M. and Doenhoff, M. (1983) Mechanisms of *Schistosoma mansoni* egg excretion: parasitological observations in immunosuppressed mice reconstituted with immune serum. *Parasite Immunol.*, **5**: 47-60.

33. Rowe, I.F., Soutar, A.K., Trayner, I.M., Baltz, M.L., de Beer, F.C., Walker, L., Bowyer, D., Herbert, J., Feinstein A. and Pepys, M.B. (1984) Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins. *J. Exp. Med.*, **159**: 604-616.
34. Gahring, L., Baltz, M., Pepys, M.B. and Daynes, R. (1984) Effect of ultraviolet radiation on production of epidermal cell thymocyte-activating factor/interleukin 1 *in vivo* and *in vitro*. *Proc. Natl. Acad. Sci. USA*, **81**: 1198-1202.
35. Hind, C.R.K., Collins, P.M., Renn, D., Cook, R.B., Caspi, D., Baltz, M.L. and Pepys, M.B. (1984) Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. *J. Exp. Med.*, **159**: 1058-1069.
36. Rowe, I.F., Soutar, A.K., Trayner, I.M., Thompson, G.R. and Pepys, M.B. (1984) Circulating human C-reactive protein binds very low density lipoproteins. *Clin. Exp. Immunol.*, **58**: 237-244.
37. Rowe, I.F., Baltz, M.L., Soutar, A.K. and Pepys, M.B. (1984) *In vivo* turnover studies of C-reactive protein and lipoproteins in the rabbit. *Clin. Exp. Immunol.*, **58**: 245-252.
38. Taylor, J.A., Bruton, C.J., Anderson, J.K., Mole, J.E., de Beer, F.C., Baltz, M.L. and Pepys, M.B. (1984) Amino acid sequence homology between rat and human C-reactive protein. *Biochem. J.*, **221**: 903-906.
39. Lamontagne, L.R., Gauldie, J., Befus, A.D., McAdam, K.P.W.J., Baltz, M.L. and Pepys, M.B. (1984) The acute phase response in parasite infection. *Nippostrongylus brasiliensis* in the mouse. *Immunology*, **52**: 733-742.
40. Caspi, D., Baltz, M.L., Snel, F., Gruys, E., Niv, D., Batt, R.M., Munn, E.A., Buttress, N. and Pepys, M.B. (1984) Isolation and characterization of C-reactive protein from the dog. *Immunology*, **53**: 307-313.
41. Hind, C.R.K., Collins, P.M. and Pepys, M.B. (1984) Calcium-dependent aggregation of human serum amyloid P component. Inhibition by the cyclic 4,6-pyruvate acetal of galactose. *Biochim. Biophys. Acta*, **802**: 148-150.
42. Baltz, M.L., Dyck, R.F. and Pepys, M.B. (1985) Studies of the *in vivo* synthesis and catabolism of serum amyloid P component (SAP) in the mouse. *Clin. Exp. Immunol.*, **59**: 235-242.
43. Baltz, M.L., Rowe, I.F. and Pepys, M.B. (1985) *In vivo* turnover studies of C-reactive protein. *Clin. Exp. Immunol.*, **59**: 243-250.

44. Hind, C.R.K., Collins, P.M., Baltz, M.L. and Pepys, M.B. (1985) Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. *Biochem. J.*, **225**: 107-111.
45. Rowe, I.F., Soutar, A.K. and Pepys, M.B. (1986) Agglutination of intravenous lipid emulsion ("Intralipid") and plasma lipoproteins by C-reactive protein. *Clin. Exp. Immunol.*, **66**: 241-247.
46. Maudsley, S., Hind, C.R.K., Munn, E.A., Buttress, N. and Pepys, M.B. (1986) Isolation and characterization of guinea-pig serum amyloid P component. *Immunology*, **59**: 317-322.
47. Bliven, M.L., Wooley, P.H., Pepys, M.B. and Otterness, I.G. (1986) Murine type II collagen arthritis. Association of an acute-phase response with clinical course. *Arth. Rheum.*, **29**: 1131-1138.
48. Poole, S., Gaines Das, R.E., Baltz, M. and Pepys, M.B. (1986) Detection of endotoxin in mice by measurement of endotoxin-induced changes in plasma concentrations of zinc and of the acute-phase protein serum amyloid P-component. *J. Pharm. Pharmacol.*, **38**: 807-810.
49. Maudsley, S., Rowe, I.F., de Beer, F.C., Munn, E.A., Herbert, J., Feinstein, A. and Pepys, M.B. (1987) Identification and isolation of two pentraxins from bovine serum. *Clin. Exp. Immunol.*, **67**: 662-673.
50. Maudsley, S., Baltz, M.L., Munn, E.A., Buttress, N., Herbert, J., Feinstein, A. and Pepys, M.B. (1987) Isolation and characterisation of goat C-reactive protein. *Biochim. Biophys. Acta*, **924**: 75-80.
51. Caspi, D., Snel, F.W.J.J., Batt, R.M., Bennett, D., Rutteman, G.R., Hartman, E.G., Baltz, M.L., Gruys, E. and Pepys, M.B. (1987) C-reactive protein in dogs. *Am. J. Vet. Res.*, **48**: 919-921.
52. Maudsley, S. and Pepys, M.B. (1987) Immunochemical cross-reactions between pentraxins of different species. *Immunology*, **62**: 17-22.
53. Pepys, M.B. and Butler, P.J.G. (1987) Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. *Biochem. Biophys. Res. Comm.*, **148**: 308-313.
54. Wood, S.P., Oliva, G., O'Hara, B.P., White, H.E., Blundell, T.L., Perkins, S.J., Sardharwalla, I. and Pepys, M.B. (1988) A pentameric form of human serum amyloid P component. Crystallization, X-ray diffraction and neutron scattering studies. *J. Mol. Biol.*, **202**: 169-173.

55. O'Hara, B.P., Wood, S.P., Oliva, G., White, H.E. and Pepys, M.B. (1988) Crystallizations of human serum amyloid P component (SAP). *J. Crystal Growth*, **90**: 209-212.
56. Hintner, H., Booker, J., Ashworth, J., Aubock, J., Pepys, M.B. and Breathnach, S.M. (1988) Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates *in vitro*. *J. Invest. Dermatol.*, **91**: 22-28.
57. Breathnach, S.M., Pepys, M.B. and Hintner, H. (1989) Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils. *J. Invest. Dermatol.*, **92**: 53-58.
58. Breathnach, S.M., Kofler, H., Sepp, N., Ashworth, J., Woodrow, D., Pepys, M.B. and Hinter, H. (1989) Serum amyloid P component binds to cell nuclei *in vitro* and to *in vivo* deposits of extracellular chromatin in systemic lupus erythematosus. *J. Exp. Med.*, **170**: 1433-1438.
59. Butler, P.J.G., Tennent, G.A. and Pepys, M.B. (1990) Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. *J. Exp. Med.*, **172**: 13-18.
60. Otterness, I.G., Pazoles, P.P., Moore, P.F. and Pepys, M.B. (1991) C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. *J. Rheumatology* **18**: 505-511.
61. Tennent, G.A., Butler, P.J.G., Hutton, T., Woolfitt, A.R., Harvey, D.J., Rademacher, T.W. and Pepys, M.B. (1993) Molecular characterization of *Limulus polyphemus* C-reactive protein. I. Subunit composition. *Eur. J. Biochem.*, **214**: 91-97.
62. Amatayakul-Chantler, S., Dwek, R.A., Tennent, G.A., Pepys, M.B. and Rademacher, T.W. (1993) Molecular characterization of *Limulus polyphemus* C-reactive protein. II. Asparagine-linked oligosaccharides. *Eur. J. Biochem.*, **214**: 99-110.
63. Tennent, G.A., Baltz, M.L., Osborn, G.D., Butler, P.J.G., Noble, G.E., Hawkins, P.N. and Pepys, M.B. (1993) Studies of the structure and binding properties of hamster female protein. *Immunology*, **80**: 645-651.
64. Emsley, J., White, H.E., O'Hara, B.P., Oliva, G., Srinivasan, N., Tickle I.J., Blundell, T.L., Pepys, M.B. and Wood, S.P. (1994) Structure of pentameric human serum amyloid P component. *Nature*, **367**: 338-345.
65. Pepys, M.B., Booth, S.E., Tennent, G.A., Butler, P.J.G. and Williams, D.G. (1994) Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. *Clin. Exp. Immunol.*, **97**: 152-157.

66. Hutchinson, W.L., Noble, G.E., Hawkins, P.N. and Pepys, M.B. (1994) The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes *in vivo*. *J. Clin. Invest.*, **94**: 1390-1396.
67. Srinivasan, N., White, H.E., Emsley, J., Wood, S.P., Pepys, M.B. and Blundell, T.L. (1994) Comparative analyses of pentraxins: implications for protomer assembly and ligand binding. *Structure*, **2**: 1017-1027.
68. Shrive, A.K., Cheetham, G.M.T., Holden, D., Myles, D.A.A., Turnell, W.G., Volanakis, J.E., Pepys, M.B., Bloomer, A.C. and Greenhough, T.J. (1996) Three dimensional structure of human C-reactive protein. *Nature Struct. Biology*, **3**: 346-354.
69. Srinivasan, N., Rufino, S.D., Pepys, M.B., Wood, S.P. and Blundell, T.L. (1996) A superfamily of proteins with the lectin fold. *Chemtracts-Biochem. Mol. Biol.*, **6**: 149-164.
70. Hohenester, E., Hutchinson, W.L., Pepys, M.B. and Wood, S.P. (1997) Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. *J. Mol. Biol.*, **269**: 570-578.
71. Ashton, A.W., Boehm, M.K., Gallimore, J.R., Pepys, M.B. and Perkins, S.J. (1997) Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. *J. Mol. Biol.*, **272**: 408-422.
72. Thompson, D., Pepys, M.B. and Wood, S.P. (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. *Structure*, **7**: 169-177.
73. Bickerstaff, M.C.M., Botto, M., Hutchinson, W.L., Herbert, J., Tennent, G.A., Bybee, A., Mitchell, D.A., Cook, H.T., Butler, P.J.G., Walport, M.J. and Pepys, M.B. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. *Nature Med.*, **5**: 694-697.
74. Griselli, M., Herbert, J., Hutchinson, W.L., Taylor, K.M., Sohail, M., Krausz, T. and Pepys, M.B. (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. *J. Exp. Med.*, **190**: 1733-1739.
75. Coker, A.R., Purvis, A., Baker, D., Pepys, M.B. and Wood, S.P. (2000) Molecular chaperone properties of serum amyloid P component. *FEBS Lett.*, **473**: 199-202.
76. Hutchinson, W.L., Hohenester, E. and Pepys, M.B. (2000) Human serum amyloid P component is a single uncomplexed pentamer in whole serum. *Mol. Med.*, **6**: 482-493.



77. Noursadeghi, M., Bickerstaff, M.C.M., Gallimore, J.R., Herbert, J., Cohen, J. and Pepys, M.B. (2000) Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. *Proc. Natl. Acad. Sci. USA*, **97**: 14584-14589.
78. Herbert, J., Hutchinson, W.L., Carr, J., Ives, J., Jakob-Roetne, R., Yamamura, K., Suzuki, M. and Pepys, M.B. (2002) Influenza virus infection is not affected by serum amyloid P component. *Mol. Med.*, **8**: 9-15.
79. Noursadeghi, M., Bickerstaff, M.C.M., Herbert, J., Moyes, D., Cohen, J. and Pepys, M.B. (2002) Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection. *J. Immunol.*, **169**: 913-919.
80. Thompson, D., Pepys, M.B., Tickle, I. and Wood, S. (2002) The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. *J. Mol. Biol.*, **320**: 1081-1086.
81. Hirschfield, G.M., Herbert, J., Kahan, M.C. and Pepys, M.B. (2003) Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. *J. Immunol.*, **171**: 6046-6051.
82. Hutchinson, W.L., Herbert, J., Botto, M. and Pepys, M.B. (2004) Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice. *Immunology*, **112**: 250-254.
83. Gillmore, J.D., Hutchinson, W.L., Herbert, J., Bybee, A., Mitchell, D.A., Hasserjian, R.P., Yamamura, K., Suzuki, M., Sabin, C.A. and Pepys, M.B. (2004) Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? *Immunology*, **112**: 255-264.
84. Gill, R., Kemp, J.A., Sabin, C. and Pepys, M.B. (2004) Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. *J. Cereb. Blood Flow Metab.*, **24**: 1214-1218.
85. Pepys, M.B. (2005) Reply to: Avoiding the effect of linked genes is crucial to elucidate the role of Apcs in autoimmunity. *Nature Med.*, **11**: 12-13.
86. Noursadeghi, M., Pepys, M.B., Gallimore, R. and Cohen, J. (2005) Relationship of granulocyte colony stimulating factors with other acute phase reactants in man. *Clin. Exp. Immunol.*, **140**: 97-100.

87. Clapp, B.R., Hirschfield, G.M., Storry, C., Gallimore, J.R., Stidwill, R.P., Singer, M., Deanfield, J.E., MacAllister, R.J., Pepys, M.B., Vallance, P. and Hingorani, A.D. (2005) Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. *Circulation*, **111**: 1530-1536.

#### *Clinical studies*

1. Pepys, M.B., Dash, A.C., Markham, R.E., Thomas, H.C., Williams, B.D. and Petrie, A. (1978) Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. *Clin. Exp. Immunol.*, **32**: 119-124.
2. Becker, G.J., Waldburger, M., Hughes, G.R.V. and Pepys, M.B. (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. *Ann. Rheum. Dis.*, **39**: 50-52.
3. Pereira Da Silva, J.A., Elkon, K.B., Hughes, G.R.V., Dyck, R.F. and Pepys, M.B. (1980) C-reactive protein levels in systemic lupus erythematosus: a classification criterion? *Arth. Rheum.*, **23**: 770-771.
4. Dyck, R.F., Evans, D.J., Lockwood, C.M., Rees, A.J., Turner, D. and Pepys, M.B. (1980) Amyloid P-component in human glomerular basement membrane. Abnormal patterns of immunofluorescent staining in glomerular disease. *Lancet*, **ii**: 606-609.
5. Breathnach, S.M., Bhogal, B., Dyck, R.F., de Beer, F.C., Black, M.M. and Pepys, M.B. (1981) Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. *Brit. J. Dermatol.*, **105**: 115-124.
6. Shine, B., de Beer, F.C. and Pepys, M.B. (1981) Solid phase radioimmunoassays for human C-reactive protein. *Clin. Chim. Acta*, **117**: 13-23.
7. Mallya, R.K., Berry, H., Mace, B.E.W., de Beer, F.C. and Pepys, M.B. (1982) Diurnal variation of erythrocyte sedimentation rate related to feeding. *Lancet*, **i**: 389-390.
8. de Beer, F.C., Hind, C.R.K., Fox, K.M., Allan, R., Maseri, A. and Pepys, M.B. (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. *Brit. Heart J.*, **47**: 239-243.
9. Mallya, R.K., Vergani, D., Tee, D.E.H., Bevis, L., de Beer, F.C., Berry, H., Hamilton, E.D.B., Mace, B.E.W. and Pepys, M.B. (1982) Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. *Clin. Exp. Immunol.*, **48**: 747-753.

10. Mallya, R.K., de Beer, F.C., Berry, H., Hamilton, E.D.B., Mace, B.E.W. and Pepys, M.B. (1982) Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. *J. Rheumatol.*, **9**: 224-228.
11. Fagan, E.A., Dyck, R.F., Maton, P.N., Hodgson, H.J.F., Chadwick, V.S., Petrie, A. and Pepys, M.B. (1982) Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. *Eur. J. Clin. Invest.*, **12**: 351-359.
12. Jensson, Ó., Björnsson, Ó.G., Árnason, A., Birgisdóttir, B. and Pepys, M.B. (1982) Serum amyloid P-component and C-reactive protein in serum of healthy Icelanders and members of an Icelandic family with macroglobulinaemia. *Acta Med. Scand.*, **211**: 341-345.
13. Breathnach, S.M., Melrose, S.M., Bhogal, B., de Beer, F.C., Black, M.M. and Pepys, M.B. (1982) Immunohistochemical studies of amyloid P component in disorders of cutaneous elastic tissue. *Brit. J. Dermatol.*, **107**: 443-452.
14. Haas, R.H., Dyck, R.F., Dubowitz, V. and Pepys, M.B. (1982) C-reactive protein in childhood dermatomyositis. *Ann. Rheum. Dis.*, **41**: 483-485.
15. Lanham, K., de Beer, F.C., Hughes, G.R.V. and Pepys, M.B. (1983) Significance of CRP elevation in SLE. *Scand. J. Rheumatol.*, **12**: 64.
16. Mallya, R.K., Young, B.J.J., Pepys, M.B., Hamblin, T.J., Mace, B.E.W. and Hamilton, E.B.D. (1983) Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. *Clin. Exp. Immunol.*, **51**: 17-20.
17. Breathnach, S.M., Melrose, S.M., Bhogal, B., de Beer, F.C., Black, M.M. and Pepys, M.B. (1983) Ultrastructural localization of amyloid P component in primary localized cutaneous amyloidosis. *Clin. Exp. Dermatol.*, **8**: 355-362.
18. Breathnach, S.M., Bhogal, B., de Beer, F.C., Melrose, S.M., Black, M.M. and Pepys, M.B. (1983) Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria. *Brit. J. Dermatol.*, **108**: 267-275.
19. Dornan, T.L., Rhymes, I.L., Cederholm-Williams, S.A., Rizza, C.R., Pepys, M.B., Bron, A.J. and Turner, R.C. (1983) Plasma haemostatic factors and diabetic retinopathy. *Eur. J. Clin. Invest.*, **13**: 231-235.
20. Moutsopoulos, H.M., Elkon, K.B., Mavridis, A.K., Acritidis, N.C., Hughes, G.R.V. and Pepys, M.B. (1983) Serum C-reactive protein in primary Sjögren's syndrome. *Clin. Exp. Rheumat.*, **1**: 57-58.

21. Saverymuttu, S.H., Peters, A.M., Lavender, J.P., Pepys, M.B., Hodgson, H.J.F. and Chadwick, V.S. (1983) Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. *Gastroenterology*, **85**: 1333-1339.
22. Cox, M.L., Freeman, H.G.M., Hodgkinson, H.M., Pepys, M.B. and Ogle, S.J. (1983) Serum proteins in the elderly. Reference Ranges II. *J. Clin. Exp. Gerontol.*, **5**: 295-302.
23. Starke, I.D., de Beer, F.C., Donnelly, J.P., Catovsky, D., Goldman, J.M., Galton, D.A.G. and Pepys, M.B. (1984) Serum C-reactive protein levels in the management of infection in acute leukaemia. *Eur. J. Cancer Clin. Oncol.*, **20**: 319-325.
24. Kenny, R.A., Hodgkinson, H.M., Cox, M.L., Caspi, D. and Pepys, M.B. (1984) Acute phase protein response to infection in elderly patients. *Age Ageing*, **13**: 89-94.
25. Winearls, C.G., Hind, C.R.K., Mason, P. and Pepys, M.B. (1984) Treatment of Wegener's granulomatosis. *Lancet*, **i**: 634-635.
26. Hind, C.R.K., Winearls, C.G., Lockwood, C.M., Rees, A.J. and Pepys, M.B. (1984) Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. *Clin. Nephrol.*, **21**: 341-345.
27. Hind, C.R.K., Savage, C.O., Winearls, C.G. and Pepys, M.B. (1984) Objective monitoring of disease activity in polyarteritis by measurement of serum C reactive protein concentration. *Brit. Med. J.*, **288**: 1027-1030.
28. Rowe, I.F., Worsley, A.M., Donnelly, P., Catovsky, D., Goldman, J.M., Galton, D.A.G. and Pepys, M.B. (1984) Measurement of serum C reactive protein concentration after bone marrow transplantation for leukaemia. *J. Clin. Pathol.*, **37**: 263-266.
29. Ridley, M.J., Ridley, D.S., de Beer, F.C. and Pepys, M.B. (1984) C-reactive protein and apoB containing lipoproteins are associated with *Mycobacterium leprae* in lesions of human leprosy. *Clin. Exp. Immunol.*, **56**: 545-552.
30. Kenny, R.A., Saunders, A.P., Coll, A., Harrington, M.G., Caspi, D., Hodgkinson, H.M. and Pepys, M.B. (1985) A comparison of the erythrocyte sedimentation rate and serum C-reactive protein concentration in elderly patients. *Age Ageing*, **14**: 15-20.
31. Hind, C.R.K., Thomas, A.M.K., Pepys, M.B. and Allison, D.J. (1985) Serum C-reactive protein response to therapeutic embolisation: possible role in management. *Clin. Radiol.*, **36**: 179-183.

32. Bending, J.J., Pickup, J.C., Rowe, I.F., Gallimore, R., Tennent, G., Keen, H. and Pepys, M.B. (1985) Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein. *Diabetologia*, **28**: 113-115.
33. Rowe, I.F., Walker, L.N., Bowyer, D.E., Soutar, A.K., Smith, L.C. and Pepys, M.B. (1985) Immunohistochemical studies of C-reactive protein and apolipoprotein B in inflammatory and arterial lesions. *J. Pathol.*, **145**: 241-249.
34. Hind, C.R.K., Winearls, C.G. and Pepys, M.B. (1985) Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients. *Eur. J. Clin. Invest.*, **15**: 89-94.
35. Mallya, R.K., Hind, C.R.K., Berry, H. and Pepys, M.B. (1985) Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study. *Arth. Rheum.*, **28**: 383-387.
36. Hind, C.R.K., Thomson, S.P., Winearls, C.G. and Pepys, M.B. (1985) Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis. *J. Clin. Pathol.*, **38**: 459-463.
37. Hind, C.R.K., Ng, S.C., Feng, P.H. and Pepys, M.B. (1985) Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. *Ann. Rheum. Dis.*, **44**: 260-261.
38. Boralessa, H., de Beer, F.C., Manchie, A., Whitwam, J.G. and Pepys, M.B. (1986) C-reactive protein in patients undergoing cardiac surgery. *Anaesthesia*, **41**: 11-15.
39. Sleightholm, M.A., Gallimore, R., Tennent, G.A., Rowe, I.F., Kohner, E.M. and Pepys, M.B. (1986) Continuous subcutaneous insulin infusion does not provoke significant acute-phase response. *Diabetes Care*, **9**: 50-52.
40. Saverymuttu, S.H., Hodgson, H.J.F., Chadwick, V.S. and Pepys, M.B. (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. *Gut*, **27**: 809-813.
41. Cox, M.L., Rudd, A.G., Gallimore, R., Hodgkinson, H.M. and Pepys, M.B. (1986) Real-time measurement of serum C-reactive protein in the management of infection in the elderly. *Age Ageing*, **15**: 257-266.
42. Rowe, I.F., Magoha, G.A., El Malik, F., Whitwam, J.G., Williams, G. and Pepys, M.B. (1987) Measurement of serum C-reactive protein concentration after renal transplantation. *Nephrol. Dial. Transplant.*, **2**: 39-41.

43. Wasunna, A., Whitelaw, A., Gallimore, R., Hawkins, P.N. and Pepys, M.B. (1990) C-reactive protein and bacterial infection in preterm infants. *Eur. J. Pediatr.*, **149**: 424-427.
44. Nelson, S.R., Tennent, G.A., Sethi, D., Gower, P.E., Ballardie, F.W., Amatayakul-Chantler, S. and Pepys, M.B. (1991) Serum amyloid P component in chronic renal failure and dialysis. *Clin. Chim. Acta*, **200**: 191-200.
45. Vigushin, D.M., Pepys, M.B. and Hawkins, P.N. (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. *J. Clin. Invest.*, **91**: 1351-1357.
46. Stuart, J., Stone, P.C.W., Akinola, N.O., Gallimore, J.R. and Pepys, M.B. (1994) Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. *J. Clin. Pathol.*, **47**: 166-169.
47. Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebuzzi, A.G., Pepys, M.B. and Maseri, A. (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. *N. Engl. J. Med.*, **331**: 417-424.
48. Liuzzo, G., Biasucci, L.M., Rebuzzi, A.G., Gallimore, J.R., Caligiuri, G., Lanza, G.A., Quaranta, G., Monaco, C., Pepys, M.B. and Maseri, A. (1996) Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. *Circulation*, **94**: 2373-2380.
49. Hartmann, A., Eide, T.C., Fauchald, P., Bentdal, Ø., Herbert, J., Gallimore, J.R. and Pepys, M.B. (1997) Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. *Nephrol. Dial. Transplant.*, **12**: 161-166.
50. Haverkate, F., Thompson, S.G., Pyke, S.D.M., Gallimore, J.R. and Pepys, M.B. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. *Lancet*, **349**: 462-466.
51. Hogarth, M.B., Gallimore, J.R., Savage, P., Palmer, A.J., Starr, J.M., Bulpitt, C.J. and Pepys, M.B. (1997) Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient. *Age Ageing*, **26**: 153-158.
52. Spector, T.D., Hart, D.J., Nandra, D., Doyle, D.V., Mackillop, N., Gallimore, J.R. and Pepys, M.B. (1997) Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. *Arthritis Rheum.*, **40**: 723-727.

53. van Leeuwen, M.A., van Rijswijk, M.H., Sluiter, W.J., van Riel, P.L.C.M., Kuper, I.H., van de Putte, L.B.A., Pepys, M.B. and Limburg, P.C. (1997) Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. *J. Rheumatol.*, **24**: 20-27.
54. Wilkins, J., Gallimore, J.R., Moore, E.G. and Pepys, M.B. (1998) Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. *Clin. Chem.*, **44**: 1358-1361.
55. Liuzzo, G., Buffon, A., Biasucci, L.M., Gallimore, J.R., Caligiuri, G., Vitelli, A., Altamura, S., Ciliberto, G., Rebuzzi, A.G., Crea, F., Pepys, M.B. and Maseri, A. (1998) Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. *Circulation*, **98**: 2370-2376.
56. Koenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W.L. and Pepys, M.B. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation*, **99**: 237-242.
57. Danesh, J., Muir, J., Wong, Y.-K., Ward, M., Gallimore, J.R. and Pepys, M.B. (1999) Risk factors for coronary heart disease and acute-phase proteins. A population-based study. *Eur. Heart J.*, **20**: 954-959.
58. Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Caligiuri, G., Buffon, A., Rebuzzi, A.G., Pepys, M.B. and Maseri, A. (1999) Enhanced inflammatory response in patients with preinfarction unstable angina. *J. Am. Coll. Cardiol.*, **34**: 1696-1703.
59. Koenig, W., Rothenbacher, D., Hoffmeister, A., Miller, M., Bode, G., Adler, G., Hombach, V., März, W., Pepys, M.B. and Brenner, H. (1999) Infection with *Helicobacter pylori* is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. *Circulation*, **100**: 2326-2331.
60. Fröhlich, M., Döring, A., Imhof, A., Hutchinson, W.L., Pepys, M.B. and Koenig, W. (1999) Oral contraceptive use is associated with a systemic acute phase response. *Fibrinolysis & Proteolysis*, **13**: 239-244.
61. Hutchinson, W.L., Koenig, W., Fröhlich, M., Sund, M., Lowe, G.D.O. and Pepys, M.B. (2000) Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. *Clin. Chem.*, **46**: 934-938.

62. Danesh, J., Whincup, P., Walker, M., Lennon, L., Thomson, A., Appleby, P., Gallimore, J.R. and Pepys, M.B. (2000) Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. *B.M.J.*, **321**: 199-204.
63. Fröhlich, M., Imhof, A., Berg, G., Hutchinson, W.L., Pepys, M.B., Boeing, H., Muche, R., Brenner, H. and Koenig, W. (2000) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. *Diabetes Care*, **23**: 1835-1839.
64. Imhof, A., Froehlich, M., Brenner, H., Boeing, H., Pepys, M.B. and Koenig, W. (2001) Effect of alcohol consumption on systemic markers of inflammation. *Lancet*, **357**: 763-767.
65. Chambers, J.C., Eda, S., Bassett, P., Karim, Y., Thompson, S.G., Gallimore, J.R., Pepys, M.B. and Kooner, J.S. (2001) C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. *Circulation*, **104**: 145-150.
66. Peters, A., Fröhlich, M., Döring, A., Immervoll, T., Wichmann, H.-E., Hutchinson, W.L., Pepys, M.B. and Koenig, W. (2001) Particulate air pollution is associated with an acute phase response in man. Results from the MONICA-Augsburg Study. *Eur. Heart J.*, **22**: 1198-1204.
67. Fröhlich, M., Sund, M., Thorand, B., Hutchinson, W.L., Pepys, M.B. and Koenig, W. (2002) Lack of seasonal variation in C-reactive protein. *Clin. Chem.*, **48**: 575-577.
68. Fröhlich, M., Mühlberger, N., Hanke, H., Imhof, A., Döring, A., Pepys, M.B. and Koenig, W. (2003) Markers of inflammation in women on different hormone replacement therapies. *Ann. Med.*, **35**: 353-361.
69. Koenig, W., Sund, M., Fröhlich, M., Löwel, H., Hutchinson, W.L. and Pepys, M.B. (2003) Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time. The MONICA Augsburg Studies, 1984 and 1987. *Am. J. Epidemiol.*, **158**: 357-364.
70. Khuseyinova, N., Imhof, A., Trischler, G., Rothenbacher, D., Hutchinson, W.L., Pepys, M.B. and Koenig, W. (2003) Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. *Clin. Chem.*, **49**: 1691-1695.
71. MacGregor, A.J., Gallimore, J.R., Spector, T.D. and Pepys, M.B. (2004) Genetic effects on baseline values of C-reactive protein and serum amyloid A protein: a comparison of monozygotic and dizygotic twins. *Clin. Chem.*, **50**: 130-134.



72. Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D.O., Pepys, M.B. and Gudnason, V. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N. Engl. J. Med.*, **350**: 1387-1397.
73. Greenfield, J.R., Samaras, K., Jenkins, A.B., Kelly, P.J., Spector, T.D., Gallimore, J.R., Pepys, M.B. and Campbell, L.V. (2004) Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. *Circulation*, **109**: 3022-3028.
74. Gomma, A.H., Hirschfield, G.M., Gallimore, J.R. Jr., Lowe, G.D.O., Pepys, M.B. and Fox, K.M. (2004) Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. *Am. Heart J.*, **147**: 1071-1077.

### C. *Amyloidosis*

1. Pepys, M.B., Dyck, R.F., de Beer, F.C., Skinner, M. and Cohen, A.S. (1979) Binding of serum amyloid P-component (SAP) by amyloid fibrils. *Clin. Exp. Immunol.*, **38**: 284-293.
2. Baltz, M.L., Gomer, K., Davies, A.J.S., Evans, D.J., Klaus, G.G.B. and Pepys, M.B. (1980) Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. *Clin. Exp. Immunol.*, **39**: 355-360.
3. Baltz, M.L., Dyck, R.F. and Pepys, M.B. (1980) Amyloid P-component in mice injected with casein: identification in amyloid deposits and in the cytoplasm of hepatocytes. *Immunology*, **41**: 59-66.
4. Lanham, J.G., Meltzer, M.L., de Beer, F.C., Hughes, G.R.V. and Pepys, M.B. (1982) Familial amyloidosis of Ostertag. *Q. J. Med.*, **51**: 25-32.
5. de Beer, F.C., Mallya, R.K., Fagan, E.A., Lanham, J.G., Hughes, G.R.V. and Pepys, M.B. (1982) Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. *Lancet*, **ii**: 231-234.
6. Breathnach, S.M., Bhogal, B., de Beer, F.C., Black, M.M. and Pepys, M.B. (1982) Primary localized cutaneous amyloidosis: dermal amyloid deposits do not bind antibodies to amyloid A protein, prealbumin or fibronectin. *Brit. J. Dermatol.*, **107**: 453-459.
7. Hind, C.R.K., Tennent, G.A., Evans, D.J. and Pepys, M.B. (1983) Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma. *J. Pathol.*, **139**: 159-166.

8. Caspi, D., Baltz, M.L., Feinstein, A., Munn, E.A. and Pepys, M.B. (1984) 'Amyloid degrading activity' of human serum, an *in vitro* clearing effect which does not involve degradation of amyloid fibrils. *Clin. Exp. Immunol.*, **57**: 647-656.
9. Baltz, M.L., Caspi, D., Glatthaar, B.E., Moser, U. and Pepys, M.B. (1984) The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis. *Clin. Exp. Immunol.*, **57**: 657-662.
10. Hind, C.R.K., Gibson, D.G., Lavender, J.P. and Pepys, M.B. (1984) Non-invasive demonstration of cardiac involvement in acquired forms of systemic amyloidosis. *Lancet*, **i**: 1417.
11. Hind, C.R.K., Collins, P.M., Caspi, D., Baltz, M.L. and Pepys, M.B. (1984) Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. *Lancet*, **ii**: 376-378.
12. Rowe, I.F., Jensson, O., Lewis, P.D., Candy, J., Tennent, G.A. and Pepys, M.B. (1984) Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis. *Neuropath. App. Neurobiol.*, **10**: 53-61.
13. Neild, G.H., Scott, G.W., Rowe, I.F. and Pepys, M.B. (1985) Amyloid (type AA) in a patient with hypogammaglobulinemia. *N. Engl. J. Med.*, **312**: 446.
14. Baltz, M.L., Caspi, D., Evans, D.J., Rowe, I.F., Hind, C.R.K. and Pepys, M.B. (1986) Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. *Clin. Exp. Immunol.*, **66**: 691-700.
15. Baltz, M.L., Rowe, I.F., Caspi, D., Turnell, W.G. and Pepys, M.B. (1986) Is the serum amyloid A protein in acute phase plasma high density lipoprotein the precursor of AA amyloid fibrils? *Clin. Exp. Immunol.*, **66**: 701-708.
16. Turnell, W., Sarra, R., Glover, I.D., Baum, J.O., Caspi, D., Baltz, M.L. and Pepys, M.B. (1986) Secondary structure prediction of human SAA<sub>1</sub>. Presumptive identification of calcium and lipid binding sites. *Mol. Biol. Med.*, **3**: 387-407.
17. Turnell, W., Sarra, R., Baum, J.O., Caspi, D., Baltz, M.L. and Pepys, M.B. (1986) X-ray scattering and diffraction by wet gels of AA amyloid fibrils. *Mol. Biol. Med.*, **3**: 409-424.
18. Ballardie, F.W., Kerr, D.N.S., Tennent, G. and Pepys, M.B. (1986) Haemodialysis versus CAPD: equal predisposition to amyloidosis? *Lancet*, **i**: 795-796.
19. Baltz, M.L., Rowe, I.F., Caspi, D., Turnell, W.G. and Pepys, M.B. (1987) Acute-phase high-density lipoprotein in the rat does not contain serum amyloid A protein. *Biochem. J.*, **242**: 301-303.

20. Baltz, M.L., Pepys, M.B., Moser, U. and Glatthaar, B. (1987) Effect of vitamin C-dietary supplementation on survival in amyloidosis. *Arth. Rheum.*, **30**: 718-719.
  21. Caspi, D., Zalzman, S., Baratz, M., Teitelbaum, Z., Yaron, M., Pras, M., Baltz, M.L. and Pepys, M.B. (1987) Imaging of experimental amyloidosis with <sup>131</sup>I-labeled serum amyloid P component. *Arth. Rheum.*, **30**: 1303-1306.
  22. Hawkins, P.N., Myers, M.J., Epenetos, A.A., Caspi, D. and Pepys, M.B. (1988) Specific localization and imaging of amyloid deposits *in vivo* using <sup>123</sup>I-labeled serum amyloid P component. *J. Exp. Med.*, **167**: 903-913.
  23. Dische, F.E., Wernstedt, C., Westermark, G.T., Westermark, P., Pepys, M.B., Rennie, J.A., Gilbey, S.G. and Watkins, P.J. (1988) Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. *Diabetologia*, **31**: 158-161.
  24. Hawkins, P.N., Myers, M.J., Lavender, J.P. and Pepys, M.B. (1988) Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. *Lancet*, **i**: 1413-1418.
  25. Wens, R., Goffin, Y., Pepys, M.B., Kutnowski, M., van Beers, D., Decoodt, P. and Verbanck, M. (1989) Left atrial myxoma associated with systemic AA amyloidosis. *Arch. Int. Med.*, **149**: 453-454.
  26. Snel, F.W.J.J., Niewold, Th.A., Baltz, M.L., Hol, P.R., van Ederen, A.M., Pepys, M.B. and Gruys, E. (1989) Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition. *Clin. Exp. Immunol.*, **76**: 296-300.
  27. Hawkins, P.N. and Pepys, M.B. (1990) A primed state exists *in vivo* following histological regression of amyloidosis. *Clin. Exp. Immunol.*, **81**: 325-328.
  28. Hawkins, P.N., Lavender, J.P. and Pepys, M.B. (1990) Evaluation of systemic amyloidosis by scintigraphy with <sup>123</sup>I-labeled serum amyloid P component. *N. Engl. J. Med.*, **323**: 508-513.
  29. Hawkins, P.N., Wootton, R. and Pepys, M.B. (1990) Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. *J. Clin. Invest.*, **86**: 1862-1869.
- Nelson, S.R., Lyon, M., Gallagher, J.T., Johnson, E.A. and Pepys, M.B. (1991) Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. *Biochem. J.*, **273**: 67-73.

31. Nelson, S.R., Hawkins, P.N., Richardson, S., Lavender, J.P., Sethi, D., Gower, P.E., Pugh, C.W., Winearls, C.G., Oliver, D.O. and Pepys, M.B. (1991) Imaging of haemodialysis-associated amyloidosis with  $^{123}\text{I}$ -serum amyloid P component. *Lancet*, **338**: 335-339.
32. Holmgren, G., Steen, L., Ekstedt, J., Groth, C.-G., Ericzon, B.-G., Eriksson, S., Andersen, O., Karlberg, I., Norden, G., Nakazato, M., Hawkins, P., Richardson, S. and Pepys, M. (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met<sup>30</sup>). *Clin. Genetics*, **40**: 242-246.
33. Hawkins, P.N., Tyrrell, P., Jones, T., Rossor, M.N., Roques, P., Myers, M., Lambrecht, R., Richardson, S., Gudmundsson, G. and Pepys, M.B. (1991) Metabolic and scintigraphic studies with radiolabelled serum amyloid P component in amyloidosis: applications to cerebral deposits and Alzheimer disease with positron emission tomography. *Bull. Clin. Neurosci.*, **56**: 178-190.
34. Hawkins, P.N., Tennent, G.A., Woo, P. and Pepys, M.B. (1991) Studies *in vivo* and *in vitro* of serum amyloid P component in normals and in a patient with AA amyloidosis. *Clin. Exp. Immunol.*, **84**: 308-316.
35. Solomon, A., Weiss, D.T. and Pepys, M.B. (1992) Induction in mice of human light-chain-associated amyloidosis. *Am. J. Pathol.*, **140**: 629-637.
36. Soutar, A.K., Hawkins, P.N., Vigushin, D.M., Tennent, G.A., Booth, S.E., Hutton, T., Nguyen, O., Totty, N.F., Feest, T.G., Hsuan, J.J. and Pepys, M.B. (1992) Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. *Proc. Natl. Acad. Sci. USA*, **89**: 7389-7393.
37. Pepys, M.B., Hawkins, P.N., Booth, D.R., Vigushin, D.M., Tennent, G.A., Soutar, A.K., Totty, N., Nguyen, O., Blake, C.C.F., Terry, C.J., Feest, T.G., Zalin, A.M. and Hsuan, J.J. (1993) Human lysozyme gene mutations cause hereditary systemic amyloidosis. *Nature*, **362**: 553-557.
38. Holmgren, G., Ericzon, B.-G., Groth, C.-G., Steen, L., Suhr, O., Andersen, O., Wallin, B.G., Seymour, A., Richardson, S., Hawkins, P.N. and Pepys, M.B. (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. *Lancet*, **341**: 1113-1116.
39. Hawkins, P.N., Richardson, S., MacSweeney, J.E., King, A.D., Vigushin, D.M., Lavender, J.P. and Pepys, M.B. (1993) Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. *Q. J. Med.*, **86**: 365-374.

40. Hawkins, P.N., Richardson, S., Vigushin, D.M., David, J., Kelsey, C.R., Gray, R.E.S., Hall, M.A., Woo, P., Lavender, J.P. and Pepys, M.B. (1993) Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. *Arthritis Rheum.*, **36**: 842-851.
41. Pepys, M.B., Rademacher, T.W., Amatayakul-Chantler, S., Williams, P., Noble, G.E., Hutchinson, W.L., Hawkins, P.N., Nelson, S.R., Gallimore, J.R., Herbert, J., Hutton, T. and Dwek, R.A. (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. *Proc. Natl. Acad. Sci. USA*, **91**: 5602-5606.
42. Vigushin, D.M., Gough, J., Allan, D., Alguacil, A., Penner, B., Pettigrew, N.M., Quinonez, G., Bernstein, K., Booth, S.E., Booth, D.R., Soutar, A.K., Hawkins, P.N. and Pepys, M.B. (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. *Q. J. Med.*, **87**: 149-154.
43. Vigushin, D.M., Hawkins, P.N., Hsuan, J.J., Totty, N.F. and Pepys, M.B. (1994) AL $\kappa$  amyloid in a solitary extradural lymphoma. *J. Neurol. Neurosurg. Psychiatry*, **57**: 751-754.
44. Hawkins, P.N., Rossor, M.N., Gallimore, J.R., Miller, B., Moore, E.G. and Pepys, M.B. (1994) Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. *Biochem. Biophys. Res. Commun.*, **201**: 722-726.
45. Wilkins, J., Gallimore, J.R., Tennent, G.A., Hawkins, P.N., Limburg, P.C., van Rijswijk, M.H., Moore, E.G. and Pepys, M.B. (1994) Rapid automated enzyme immunoassay of serum amyloid A. *Clin. Chem.*, **40**: 1284-1290.
46. Tan, S.Y., Murdoch, I.E., Sullivan, T.J., Wright, J.E., Truong, O., Hsuan, J.J., Hawkins, P.N. and Pepys, M.B. (1994) Primary localized orbital amyloidosis composed of the immunoglobulin  $\gamma$  heavy chain CH3 domain. *Clin. Sci.*, **87**: 487-491.
47. Booth, D.R., Tan, S.Y., Hawkins, P.N., Pepys, M.B. and Frustaci, A. (1995) A novel variant of transthyretin, 59<sup>Thr→Lys</sup>, associated with autosomal dominant cardiac amyloidosis in an Italian family. *Circulation*, **91**: 962-967.
48. Tennent, G.A., Lovat, L.B. and Pepys, M.B. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. *Proc. Natl. Acad. Sci. USA*, **92**: 4299-4303.
49. Harvey, C.J., Gower, P.E., Hawkins, P.N., Pepys, M.B. and Phillips, M.E. (1995) Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure. *Nephrol. Dial. Transplant.*, **10**: 1237-1239.

50. Lovat, L.B., Booth, S.E., Booth, D.R., Madhoo, S., Holmgren, G., Hawkins, P.N., Soutar, A.K. and Pepys, M.B. (1995) Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. *Amyloid: Int. J. Exp. Clin. Invest.*, **2**: 163-166.
51. Booth, D.R., Tan, S.Y., Booth, S.E., Hsuan, J.J., Totty, N.F., Nguyen, O., Hutton, T., Vigushin, D.M., Tennent, G.A., Hutchinson, W.L., Thomson, N., Soutar, A.K., Hawkins, P.N. and Pepys, M.B. (1995) A new apolipoprotein AI variant, Trp50Arg, causes hereditary amyloidosis. *Q. J. Med.*, **88**: 695-702.
52. Reilly, M.M., Adams, D., Booth, D.R., Davis, M.B., Said, G., Laubriat-Bianchin, M., Pepys, M.B., Thomas, P.K. and Harding, A.E. (1995) Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. *Brain*, **118**: 849-856.
53. Booth, D.R., Tan, S.Y., Booth, S.E., Tennent, G.A., Hutchinson, W.L., Hsuan, J.J., Totty, N.F., Truong, O., Soutar, A.K., Hawkins, P.N., Bruguera, M., Caballería, J., Solé, M., Campistol, J.M. and Pepys, M.B. (1996) Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. *J. Clin. Invest.*, **97**: 2714-2721.
54. Tan, S.Y., Irish, A., Winearls, C.G., Brown, E.A., Gower, P.E., Clutterbuck, E.J., Madhoo, S., Lavender, J.P., Pepys, M.B. and Hawkins, P.N. (1996) Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. *Kidney Int.*, **50**: 282-289.
55. Murdoch, I.E., Sullivan, T.J., Moseley, I., Hawkins, P.N., Pepys, M.B., Tan, S.Y., Garner, A. and Wright, J.E. (1996) Primary localised amyloidosis of the orbit. *Br. J. Ophthalmol.*, **80**: 1083-1086.
56. Hawkins, P.N. and Pepys, M.B. (1996) Role of heart transplantation in systemic amyloidosis. *J. Heart Lung Transplant.*, **15**: 321-322.
57. Booth, D.R., Sunde, M., Bellotti, V., Robinson, C.V., Hutchinson, W.L., Fraser, P.E., Hawkins, P.N., Dobson, C.M., Radford, S.E., Blake, C.C.F. and Pepys, M.B. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. *Nature*, **385**: 787-793.
58. Lovat, L.B., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1997) Long term survival in systemic AA amyloidosis complicating Crohn's disease. *Gastroenterology*, **112**: 1362-1365.
59. Botto, M., Hawkins, P.N., Bickerstaff, M.C.M., Herbert, J., Bygrave, A.E., McBride, A., Hutchinson, W.L., Tennent, G.A., Walport, M.J. and Pepys, M.B. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. *Nature Med.*, **3**: 855-859.

60. Clesham, G.J., Vigushin, D.M., Hawkins, P.N., Pepys, M.B., Oakley, C.M. and Nihoyannopoulos, P. (1997) Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. *Am. J. Cardiol.*, **80**: 1104-1108.
61. Sunde, M., Serpell, L.C., Bartlam, M., Fraser, P.E., Pepys, M.B. and Blake, C.C.F. (1997) Common core structure of amyloid fibrils by synchrotron X-ray diffraction. *J. Mol. Biol.*, **273**: 729-739.
62. Persey, M.R., Booth, D.R., Booth, S.E., van Zyl-Smit, R., Adams, B.K., Fattaar, A.B., Tennent, G.A., Hawkins, P.N. and Pepys, M.B. (1998) Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. *Kidney Int.*, **53**: 276-281.
63. Lovat, L.B., Persey, M.R., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1998) The liver in systemic amyloidosis: insights from <sup>123</sup>I serum amyloid P component scintigraphy in 484 patients. *Gut*, **42**: 727-734.
64. Stangou, A.J., Heaton, N.D., Rela, M., Pepys, M.B., Hawkins, P.N. and Williams, R. (1998) Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. *Transplantation*, **65**: 1496-1498.
65. Stangou, A.J., Hawkins, P.N., Heaton, N.D., Rela, M., Monaghan, M., Nihoyannopoulos, P., O'Grady, J., Pepys, M.B. and Williams, R. (1998) Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. *Transplantation*, **66**: 229-233.
66. Hawkins, P.N., Aprile, C., Capri, G., Viganò, L., Munzone, E., Gianni, L., Pepys, M.B. and Merlini, G. (1998) Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. *Eur. J. Nucl. Med.*, **25**: 701-708.
67. Rydh, A., Suhr, O., Hietala, S.-O., Åhlström, K.R., Pepys, M.B. and Hawkins, P.N. (1998) Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. *Eur. J. Nucl. Med.*, **25**: 709-713.
68. Lovat, L.B., O'Brien, A.A.J., Armstrong, S.F., Madhoo, S., Bulpitt, C.J., Rossor, M.N., Pepys, M.B. and Hawkins, P.N. (1998) Scintigraphy with <sup>123</sup>I-serum amyloid P component in Alzheimer disease. *Alzheimer Dis. Assoc. Disord.*, **12**: 208-210.
69. Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. (1998) SAA<sub>1</sub> alleles as risk factors in reactive systemic AA amyloidosis. *Amyloid: Int. J. Exp. Clin. Invest.*, **5**: 262-265.

70. Poole, S., Walker, D., Gaines Das, R.E., Gallimore, J.R. and Pepys, M.B. (1998) The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. *J. Immunol. Meth.*, **214**: 1-10.
71. Brett, M., Persey, M.R., Reilly, M.M., Revesz, T., Booth, D.R., Booth, S.E., Hawkins, P.N., Pepys, M.B. and Morgan-Hughes, J.A. (1999) Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. *Brain*, **122**: 183-190.
72. Tan, S.Y., Baillod, R., Brown, E., Farrington, K., Soper, C., Percy, M., Clutterbuck, E., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1999) Clinical, radiological and serum amyloid P component scintigraphic features of  $\beta_2$ -microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. *Nephrol. Dial. Transplant.*, **14**: 1467-1471.
73. Gillmore, J.D., Booth, D.R., Pepys, M.B. and Hawkins, P.N. (1999) Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. *Heart*, **82**: e2.
74. Gillmore, J.D., Booth, D.R., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1999) Hereditary renal amyloidosis associated with variant lysozyme in a large English family. *Nephrol. Dial. Transplant.*, **14**: 2639-2644.
75. Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Rahman, V., Stangou, A.J., Pepys, M.B. and Hawkins, P.N. (2000) Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen  $\alpha$ -chain variant in an English family. *Q. J. Med.*, **93**: 269-275.
76. Serpell, L.C., Sunde, M., Benson, M.D., Tennent, G.A., Pepys, M.B. and Fraser, P.E. (2000) The protofilament substructure of amyloid fibrils. *J. Mol. Biol.*, **300**: 1033-1039.
77. Booth, D.R., Pepys, M.B. and Hawkins, P.N. (2000) A novel variant of human lysozyme (T70N) is common in the normal population. *Hum. Mutat.*, **16**: 180.
78. Gillmore, J.D., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (2000) Renal transplantation for amyloid end-stage renal failure - insights from serial serum amyloid P component scintigraphy. *Nucl. Med. Commun.*, **21**: 735-740.
79. Gillmore, J.D., Lovat, L.B., Persey, M.R., Pepys, M.B. and Hawkins, P.N. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. *Lancet*, **358**: 24-29.
80. Jiménez, J.L., Tennent, G., Pepys, M. and Saibil, H.R. (2001) Structural diversity of *ex vivo* amyloid fibrils studied by cryo-electron microscopy. *J. Mol. Biol.*, **311**: 241-247.



81. Lachmann, H.J., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. (2002) Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. *Q. J. Med.*, **95**: 211-218.
82. Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Pepys, M.B. and Hawkins, P.N. (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. *N. Engl. J. Med.*, **346**: 1786-1791.
83. Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., Hoffmann, T., Jakob-Roetne, R., Norcross, R.D., Kemp, J.A., Yamamura, K., Suzuki, M., Taylor, G.W., Murray, S., Thompson, D., Purvis, A., Kolstoe, S., Wood, S.P. and Hawkins, P.N. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. *Nature*, **417**: 254-259.
84. Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. and Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. *Br. J. Haematol.*, **122**: 78-84.

#### ***D. Surface marker studies of human lymphocytes***

1. Pepys, M.B., Sategna-Guidetti, C., Mirjah, D.D., Wansbrough-Jones, M.H. and Dash, A.C. (1976) Enumeration of immunoglobulin-bearing lymphocytes in whole peripheral blood. *Clin. Exp. Immunol.*, **26**: 91-94.
2. Druguet, M. and Pepys, M.B. (1977) Enumeration of lymphocyte populations in whole peripheral blood with alkaline phosphatase-labelled reagents. A method for routine clinical use. *Clin. Exp. Immunol.*, **29**: 162-167.
3. Pepys, E.O. and Pepys, M.B. (1980) Enumeration in whole peripheral blood of lymphocytes bearing receptors for Fc( $\gamma$ ) and C3b using alkaline phosphatase-labelled reagents. *J. Immunol. Methods*, **32**: 305-314.
4. Pepys, E.O., Tennent, G.A. and Pepys, M.B. (1981) Enumeration of T and B lymphocytes in whole peripheral blood: absence of a null cell population. *Clin. Exp. Immunol.*, **46**: 229-234.
5. Pepys, E.O., Rees, A.J. and Pepys, M.B. (1982) Enumeration of lymphocyte populations in whole peripheral blood of patients with antibody-mediated nephritis during treatment with cyclosporin A. *Immunol. Letters*, **4**: 211-214.

6. Pepys, E.O., Fagan, E.A., Tennent, G.A., Chadwick, V.S. and Pepys, M.B. (1982) Enumeration of lymphocyte populations defined by surface markers in the whole blood of patients with Crohn's disease. *Gut*, **23**: 766-769.
7. Pepys, E.O., Cox, M., Hodgkinson, H.M. and Pepys, M.B. (1982) Enumeration of lymphocyte populations in whole blood of well elderly subjects. *J. Clin. Exp. Gerontol.*, **4**: 53-61.
8. Catovsky, D., Wechsler, A., Matutes, E., Gomez, R., Bourikas, G., Cherchi, M., Pepys, E.O., Pepys, M.B., Kitani, T., Hoffbrand, A.V. and Greaves, M.F. (1982) The membrane phenotype of T-prolymphocytic leukaemia. *Scand. J. Haematol.*, **29**: 398-404.

**E. Other clinical and experimental subjects**

1. Pepys, M.B. (1970) Acetazolamide and renal stone formation. *Lancet*, **i**: 837.
2. Lewis, S.M., Pettit, J.E., Tattersall, M.H.N. and Pepys, M.B. (1971) Myelosclerosis and paroxysmal nocturnal haemoglobinuria. *Scand. J. Haemat.*, **8**: 451-460.
3. Loke, Y.W. and Pepys, M.B. (1975) Effects of human chorionic gonadotropin preparations on complement *in vitro*. *Am. J. Obstet. Gyn.*, **121**: 37-40.
4. Wansbrough-Jones, M.H., Doe, W.J. and Pepys, M.B. (1976) Antigen binding cells in rabbit Peyer's patches after intestinal immunisation. *Gut*, **17(S)**: 400.
5. Wansbrough-Jones, M., Mirjah, D., Druguet, M. and Pepys, M.B. (1977) Temperature dependence of antigen-specific rosette formation by lymphocytes from immunised mice. *J. Immunol. Meth.*, **15**: 291-297.
6. Klaus, G.G.B., Pepys, M.B., Kitajima, K. and Askonas, B.A. (1979) Activation of mouse complement by different classes of mouse antibody. *Immunology*, **38**: 687-695.
7. Dawson, J., Hodgson, H.J.F., Pepys, M.B., Peters, T.J. and Chadwick, V.S. (1979) Immunodeficiency, malabsorption and secretory diarrhoea. A new syndrome. *Am. J. Med.*, **67**: 540-546.
8. Pepys, M.B., Tompkins, C. and Smith, A.D. (1979) An improved method for the isolation from *Naja naja* venom of cobra factor (CoF) free of phospholipase A. *J. Immunol. Meth.*, **30**: 105-117.
9. Druguet, M., Chayvialle, J.A.C., André, C. and Pepys, M.B. (1980) Radioimmunoassay for immunoconglutinins. *J. Immunol. Meth.*, **34**: 181-190.

10. Baltz, M.L., Ettlinger, G., Parrish, K., Pepys, M.B. and Rogers, S. (1981) Epileptic discharges produced in monkeys by injection of spleen cells from rabbits immunised with monkey brain. *J. Neurol. Sci.*, **49**: 335-340.
11. Furukawa, T., Shinkai, S., Shimamura, M., Miyazato, T., Baltz, M.L. and Pepys, M.B. (1983) Circulating immunoglobulins and complement in mice with *Hymenolepis nana* infection. *Int. J. Parasitol.*, **14**: 293-299.
12. Pepys, M.B. and Hind, C.R.K. (1984) Diagnosis of chest pain in marathon runners. *Lancet*, **i**: 278.
13. Adeyemi, E.O., Neumann, S., Chadwick, V.S., Hodgson, H.J.F. and Pepys, M.B. (1985) Circulating human leucocyte elastase in patients with inflammatory bowel disease. *Gut*, **12**: 1306-1311.
14. Pemberton, P.A., Stein, P.E., Pepys, M.B., Potter, J.M. and Carrell, R.W. (1988) Hormone binding globulins undergo serpin conformational change in inflammation. *Nature*, **336**: 257-258.
15. Pepys, M.B., Baltz, M.L., Tennent, G.A., Kent, J., Ousey, J. and Rossdale, P.D. (1989) Serum amyloid A protein (SAA) in horses: objective measurement of the acute phase response. *Equine Vet. J.*, **21**: 106-109.
16. Nelson, S.R. and Pepys, M.B. (1990) Preparative isolation of human  $\beta_2$ -microglobulin from urine. *J. Immunol. Meth.*, **128**: 277-280.
17. Hind, C.R.K., Joyce, H., Tennent, G.A., Pepys, M.B. and Pride, N.B. (1991) Plasma leucocyte elastase concentrations in smokers. *J. Clin. Pathol.*, **44**: 232-235.
18. Hintner, H., Dahlbäck, K., Dahlbäck, B., Pepys, M.B. and Breathnach, S.M. (1991) Tissue vitronectin in normal adult human dermis is non-covalently bound to elastic tissue. *J. Invest. Dermatol.*, **96**: 747-753.
19. Bristow, A.F., Gaines-Das, R.E., Buttress, N., Gallimore, J.R., Tennent, G.A. and Pepys, M.B. (1993) The International Standard for Thyroxine Binding Globulin. *Clin. Endocrinol.*, **38**: 361-366.
20. Klein, T.C., Döffinger, R., Pepys, M.B., Rüther, U. and Kyewski, B. (1995) Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice. *Eur. J. Immunol.*, **25**: 3489-3495.
21. Döffinger, R., Klein, T.C., Pepys, M.B., Casanova, J.-L. and Kyewski, B.A. (1997) The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors. *Molec. Immunol.*, **34**: 115-124.

22. Booth, D.R., Gillmore, J.D., Booth, S.E., Pepys, M.B. and Hawkins, P.N. (1998) Pyrin/marenostrin mutations in familial Mediterranean fever. *Q. J. Med.*, **91**: 603-606.
23. Tunca, M., Kirkali, G., Soytürk, M., Akar, S., Pepys, M.B. and Hawkins, P.N. (1999) Acute phase response and evolution of familial Mediterranean fever. *Lancet*, **353**: 1415.
24. Booth, D.R., Gillmore, J.D., Lachmann, H.J., Booth, S.E., Bybee, A., Soytürk, M., Akar, S., Pepys, M.B., Tunca, M. and Hawkins, P.N. (2000) The genetic basis of autosomal dominant familial Mediterranean fever. *Q. J. Med.*, **93**: 217-221.
25. Mabbott, N.A., Bruce, M.E., Botto, M., Walport, M.J. and Pepys, M.B. (2001) Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. *Nature Med.*, **7**: 485-487.
26. Pepys, M.B., Bybee, A., Booth, D.R., Bishop, M.T., Will, R.G., Little, A.-M., Prokupek, B. and Madrigal, J.A. (2003) MHC typing in variant Creutzfeldt-Jacob disease. *Lancet*, **361**: 487-489.

#### **F. History of science**

1. Pepys, M.B. (1972) Cambridge University Natural Science Club, 1872 to 1972. *Nature*, **237**: 317-319.
2. Pepys, M.B. (2003) Dame Sheila Patricia Violet Sherlock, 31 March 1918-30 December 2001. *Biogr. Mem. Fell. R. Soc. Lond.*, **49**: 475-493.

## **II. CHAPTERS, REVIEWS AND REPORTS**

1. Pepys, M.B. (1976) Characterisation and enumeration of lymphocyte populations in whole peripheral blood. Application to B cells. *In: Techniques of Separation and Characterisation of Human Lymphocytes* (Sabolovic, D. and Serrou, B., eds.), Inserm, Paris, pp. 145-151.
2. Pepys, M.B. (1976) Characterisation and enumeration of lymphocyte populations in whole human peripheral blood. *In: In vitro Methods in Cell-Mediated and Tumor Immunity* (Bloom, B.R. and Davide, J., eds.), Academic Press, New York, pp. 197-202.
3. Pepys, M.B. (1976) Immunology of the gut. *In: 12th Advanced Medicine Course, Royal College of Physicians* (Peters, D.K., ed.), Pitman Medical, Tunbridge Wells, pp. 262-274.

4. Pepys, M.B. (1978) Relationships between complement and cells. *Rev. Fr. Mal. Resp.*, **6**: 11-20.
5. Pepys, M.B. (1978) Role of complement in infectious disease. *In: New Perspectives in Clinical Microbiology* (Brumfitt, W., ed.), Kluwer-Harrap, Brentford, Middx., pp. 81-96.
6. Pepys, M.B. (1978) Experimental allergic neuritis. *In: Clinical Neuroimmunology* (Rose, F.C., ed.), Blackwell Scientific Publications, Oxford, pp. 155-164.
7. Pepys, M.B. (1979) Acute phase phenomena. *In: Science and Practice of Clinical Medicine: Rheumatology and Immunology* (Cohen, A.S., ed.), Grune and Stratton, New York, pp. 85-89.
8. Pepys, M.B. (1981) Serum C-reactive protein, serum amyloid P-component and serum amyloid A protein in autoimmune disease. *In: Autoimmunity. Clinics in Immunology and Allergy, Vol. 1* (Holborow, E.J., ed.), W.B. Saunders Co. Ltd., Eastbourne, pp. 77-101.
9. Pepys, M.B. (1981) C-reactive protein fifty years on. *Lancet*, **i**: 653-657.
10. Pepys, M.B. (1982) C-reactive protein and the acute phase response. *Immunology Today*, **3**: 27-30.
11. Pepys, M.B. (1982) Aspects of the acute phase response. The C-reactive protein system. *In: Clinical Aspects of Immunology* (Lachmann, P.J., Peters, D.K., eds.), Blackwell Scientific Publications, Oxford, pp. 50-71.
12. Pepys, M.B. (1982) C-reactive protein and the acute phase response. *Nature*, **296**: 12.
13. Pepys, M.B. (1982) C-reactive protein, amyloidosis and the acute phase response. The Goulstonian Lecture. *In: Advanced Medicine 18* (Sarner, M., ed.), Pitman Books Ltd., Tunbridge Wells, pp. 208-230.
14. Pepys, M.B. (1982) Immunology of the gastrointestinal tract. *In: Virus infections of the Gastrointestinal Tract* (Tyrell, D.A.J. and Kapikian, A., eds.), Marcel Dekker Inc., New York, pp. 89-110.
15. Pepys, M.B. (1982) C-reactive protein. A review of its structure and function. *Eur. J. Rheumatol. Inflamm.*, **5**: 386-397.
16. Pepys, M.B., Lanham, J.G. and de Beer, F.C. (1982) C-reactive protein in SLE. *In: Systemic Lupus Erythematosus, Clinics in Rheumatic Diseases, Vol. 8, No. 1* (Hughes, G.R.V., ed.), W.B. Saunders Co. Ltd., Eastbourne, pp. 91-103.

17. Pepys, M.B. (1983) C-reactive protein: the role of an ancient protein in modern rheumatology. *Clin. Exp. Rheumatol.*, **1**: 3-7.
18. Pepys, M.B. and Baltz, M.L. (1983) Acute phase proteins with particular reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. *In: Adv. Immunol., Vol. 34* (Dixon, F.J., Kunkel, H.G., eds.), Academic Press, New York, pp. 141-212.
19. Pepys, E.O. and Pepys, M.B. (1983) Demonstration of lymphocyte surface markers using alkaline phosphatase-labeled reagents. Application to the enumeration of lymphocyte populations in whole peripheral blood. *In: Methods in Enzymology, Vol. 93, Immunochemical Techniques* (van Vunakis, H. and Langone, J.L., eds.), Academic Press, New York, pp. 164-177.
20. Hind, C.R.K. and Pepys, M.B. (1984) The role of serum C-reactive protein (CRP) measurement in clinical practice. *Intern. Med. Specialist*, **5**: 112-151.
21. Hind, C.R.K. and Pepys, M.B. (1984) Amyloidosis: classification and pathogenesis (1); clinical features (2); diagnosis, prognosis and treatment (3). *Hospital Update*, **10**: 593-598, 637-648, 737-748.
22. Hind, C.R.K., Baltz, M. and Pepys, M.B. (1984) Amyloidosis. *Medicine International*, **10**: 409-416.
23. Schnebli, H.P., Christen, P., Jochum, M., Mallya, R.K. and Pepys, M.B. (1984) Plasma levels of inhibitor bound leukocyte elastase in rheumatoid arthritis patients. *In: Proteinases: Potential Role in Health and Disease* (Heidland, A. and Horl, W.H., eds.), Plenum Publishing Co., London, pp. 345-353.
24. Virca, G.D., Mallya, R.K., Pepys, M.B. and Schnebli, H.P. (1984) Quantitation of human leukocyte elastase, cathepsin G,  $\alpha_2$ -macroglobulin and  $\alpha_1$ -proteinase inhibitor in osteoarthritis and rheumatoid arthritis synovial fluids. *In: Proteinases: Potential Role in Health and Disease* (Heidland, A. and Horl, W.H., eds.), Plenum Publishing Co., London, pp. 355-362.
25. Pepys, M.B. (1985) Plasma C3d and immunoconglutinins. *In: Methods in Complement for Clinical Immunologists* (Whaley, K., ed.), Churchill Livingstone, Edinburgh, pp. 193-202.
26. Pepys, M.B., Rowe, I.F. and Baltz, M.L. (1985) C-reactive protein: binding to lipids and lipoproteins. *In: Int. Rev. Exp. Pathol., Vol. 27* (Richter, G.W. and Epstein, M.A., eds.), Academic Press, New York, pp. 83-111.
27. Pepys, M.B. and Baltz, M.L. (1986) Amyloidosis. *In: Copeman's Textbook of the Rheumatic Diseases, Sixth Edition* (Scott, J.T., ed.), Churchill Livingstone, Edinburgh, pp. 1024-1053.

28. Hind, C.R.K., Baltz, M.L. and Pepys, M.B. (1986) Amyloidosis. *In: Multiple Myeloma and other Paraproteinaemias* (Delamore, I.W., ed.), Churchill Livingstone, Edinburgh, pp. 234-262.
29. Pepys, M.B. (1987) Amyloidosis. *In: Oxford Textbook of Medicine, Second Edition* (Weatherall, D.J., Ledingham, J.G.G. and Warrell, D.A., eds.), Oxford University Press, Oxford, pp. 9.145-9.157.
30. Pepys, M.B. (1987) The acute phase response and C-reactive protein. *In: Oxford Textbook of Medicine, Second Edition* (Weatherall, D.J., Ledingham, J.G.G. and Warrell, D.A., eds.), Oxford University Press, Oxford, pp. 9.157-9.164.
31. Hind, C.R.K. and Pepys, M.B. (1987) Acute phase proteins. *In: Allergy* (Lessoof, M.H., Lee, T.H. and Kemeny, D.M., eds.), John Wiley & Sons, Chichester, pp. 237-253.
32. Pepys, M.B. (1988) Amyloidosis: some recent developments. *Q. J. Med.*, **67**: 283-298.
33. Pepys, M.B. (1988) Amyloidosis: aspects of structure, pathogenesis and management. *In: Nephrology, Volume II* (Davison, A.M., ed.), Bailliere Tindall, London, pp. 761-778.
34. Pepys, M.B. (1988) Amyloidosis. *In: Immunological Diseases, Fourth Edition, Vol. 1* (Samter, M., Talmage, D.W., Frank, M.M., Austen, K.F., Claman, H.N., eds.), Little, Brown & Co., Boston, pp. 631-674.
35. Pepys, M.B., Editor (1989) *Acute Phase Proteins in the Acute Phase Response*, Springer-Verlag, London.
36. Pepys, M.B. (1992) Acute phase proteins. *In: Encyclopedia of Immunology* (Roitt, I.M. and Delves, P.J., eds.), Saunders Scientific Publications, London, pp. 16-18.
37. Pepys, M.B. (1992) C-reactive protein. *In: Encyclopedia of Immunology* (Roitt, I.M. and Delves, P.J., eds.), Saunders Scientific Publications, London, pp. 413-414.
38. Pepys, M.B. (1992) Amyloid P component and the diagnosis of amyloidosis. *J. Int. Med.*, **232**: 519-521.
39. Pepys, M.B. (1992) Serum amyloid P component. *In: Human Protein Data* (Haeberli, A., ed.), VCH Verlagsgesellschaft mbH, Weinheim.
40. Pepys, M.B. (1993) Rheumatoid arthritis: the role of acute-phase proteins. *Br. J. Rheumatol.*, **32** (Suppl. 3): 1-2.

41. Pepys, M.B. (1994) Amyloidosis. *In: Samter's Immunologic Diseases, Fifth Edition* (Frank, M.M., Austen, K.F., Claman, H.N. and Unanue, E.R., eds.), Little, Brown & Co., Boston, pp. 637-655.
42. Tan, S.Y. and Pepys, M.B. (1994) Amyloidosis. *Histopathology*, **25**: 403-414.
43. Hawkins, P.N. and Pepys, M.B. (1995) Amyloidosis. *In: Myeloma* (Malpas, J.S., Bergsagel, D.E. and Kyle, R.A., eds.), Oxford University Press, Oxford, pp. 477-506.
44. Pepys, M.B. (1995) Acute phase proteins, C-reactive protein and serum amyloid A protein. *Rheumatology in Europe*, **24**: 26-28.
45. Hawkins, P.N. and Pepys, M.B. (1995) Imaging amyloidosis with radiolabelled SAP. *Eur. J. Nucl. Med.*, **22**: 595-599.
46. Tan, S.Y., Pepys, M.B. and Hawkins, P.N. (1995) Treatment of amyloidosis. *Am. J. Kidney Dis.*, **26**: 267-285.
47. Pepys, M.B. (1996) Amyloidosis. *In: Oxford Textbook of Medicine, Third Edition, Volume 2* (Weatherall, D.J., Ledingham, J.G.G. and Warrell, D.A., eds.), Oxford University Press, Oxford, pp. 1512-1524.
48. Pepys, M.B. (1996) The acute phase response and C-reactive protein. *In: Oxford Textbook of Medicine, Third Edition, Volume 2* (Weatherall, D.J., Ledingham, J.G.G. and Warrell, D.A., eds.), Oxford University Press, Oxford, pp. 1527-1533.
49. Hawkins, P.N., Tan, S.Y. and Pepys, M.B. (1996) Various clinical types of amyloidosis. *In: Oxford Clinical Nephrology Series: Dialysis Amyloid* (van Ypersele, C. and Drüeke, T.B., eds.), Oxford University Press, Oxford pp. 34-68.
50. Lovat, L.B., Pepys, M.B. and Hawkins, P.N. (1997) Amyloid and the gut. *Dig. Dis.*, **15**: 155-171.
51. Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. (1997) Amyloidosis: a review of recent diagnostic and therapeutic developments. *Brit. J. Haematol.*, **99**: 245-256.
52. Pepys, M.B., Booth, D.R., Hutchinson, W.L., Gallimore, J.R., Collins, P.M. and Hohenester, E. (1997) Amyloid P component. A critical review. *Amyloid: Int. J. Exp. Clin. Invest.*, **4**: 274-295.
53. Hawkins, P.N., Tan, S.Y. and Pepys, M.B. (1997) Amyloidosis. *In: Oxford Textbook of Clinical Nephrology, Second Edition, Volume 2* (Davison, A.M., Cameron, J.S., Grünfeld, J.-P., Kerr, D.N.S., Ritz, E. and Winearls, C.G.), Oxford University Press, Oxford, pp. 777-805.



54. Pepys, M.B. (1997) Serum amyloid P component. *In: Human Protein Data* (Haeberli, A., ed.), Wiley-VCH Verlag GmbH, Weinheim.
55. Hawkins, P.N. and Pepys, M.B. (1998) Amyloidosis. *In: Myeloma: Biology and Management, Second Edition* (Malpas, J.S., Bergsagel, D.E., Kyle, R.A. and Anderson, K., eds.), Oxford University Press, Oxford, pp. 559-603.
56. Pepys, M.B. (1998) Acute phase proteins. *In: Encyclopedia of Immunology, Second Edition* (Delves, P.J. and Roitt, I.M., eds.), Academic Press Ltd, London, pp. 18-20.
57. Pepys, M.B. (1998) C-reactive protein. *In: Encyclopedia of Immunology, Second Edition* (Delves, P.J. and Roitt, I.M., eds.), Academic Press Ltd, London, pp. 663-665.
58. Pepys, M.B. (1999) The Lumleian Lecture. C-reactive protein and amyloidosis: from proteins to drugs? *In: Horizons in Medicine, Number 10* (Williams, G., ed.), Royal College of Physicians, London, pp. 397-414.
59. Pepys, M.B. (1999) Serum amyloid P component. *Nature Med.*, **5**: 852-853.
60. Danesh, J. and Pepys, M.B. (2000) C-reactive protein in healthy and in sick populations. *Eur. Heart J.*, **21**: 1564-1565.
61. Pepys, M.B. and Berger, A. (2001) The renaissance of C reactive protein. It may be a marker not only of acute illness but also of future cardiovascular disease. *B.M.J.*, **322**: 4-5.
62. Pepys, M.B. and Hawkins, P.N. (2001) Amyloidosis. *In: Samter's Immunologic Diseases, Sixth Edition, Volume 1* (Austen, K.F., Frank, M.M., Atkinson, J.P. and Cantor, H., eds.), Lippincott Williams & Wilkins, Philadelphia, pp. 401-412.
63. Pepys, M.B. (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. *Phil. Trans. R. Soc. Lond. B*, **356**: 203-211.
64. Pepys, M.B. and Hirschfield, G. (2001) C-reactive protein and atherothrombosis. *Ital. Heart J.*, **2**: 196-199.
65. Pepys, M.B. and Hirschfield, G. (2001) C-reactive protein and its role in the pathogenesis of myocardial infarction. *Ital. Heart J.*, **2**: 804-806.
66. Koenig, W. and Pepys, M.B. (2002) C-reactive protein risk prediction: low specificity, high sensitivity. *Ann. Intern. Med.*, **136**: 550-552.

67. Pepys, M.B. (2003) The acute phase response and C-reactive protein. *In: Oxford Textbook of Medicine, Fourth Edition, Volume 2* (Warrell, D.A., Cox, T.M., Firth, J.D. and Benz, E.J., Jr., eds.), Oxford University Press, Oxford, pp. 150-156.
68. Pepys, M.B. and Hawkins, P.N. (2003) Amyloidosis. *In: Oxford Textbook of Medicine, Fourth Edition, Volume 2* (Warrell, D.A., Cox, T.M., Firth, J.D. and Benz, E.J., Jr., eds.), Oxford University Press, Oxford, pp. 162-173.
69. Pepys, M.B. and Hirschfield, G. (2003) C-reactive protein: a critical update. *J. Clin. Invest.*, **111**: 1805-1812.
70. Hirschfield, G.M. and Pepys, M.B. (2003) C-reactive protein and cardiovascular disease: new insights from an old molecule. *Q.J. Med.*, **96**: 793-807.

### III. CONFERENCE PROCEEDINGS

1. Pepys, M.B. (1974) Complement interactions with membranes. *Progr. Immunol. II*, **1**: 301-304.
2. Feldmann, M., Basten, A., Boylston, A., Erb, P., Gorczynski, R., Greaves, M., Hogg, N., Kilburn, D., Kontainen, S., Parker, D., Pepys, M.B. and Schrader, J. (1974) Interactions between T and B lymphocytes and accessory cells in antibody production. *Progr. Immunol. II*, **3**: 65-75.
3. Pepys, M.B., Druguet, M., Klass, H.J., Dash, A.C. and Petrie, A. (1977) Immunological studies in inflammatory bowel disease. *In: Immunology of the Gut, Ciba Foundation Symposium* (Porter, R. and Knight, J., eds.), Elsevier/Excerpta Medica/North Holland, Amsterdam, pp. 283-297.
4. Dyck, R.F., Kershaw, M., McHugh, N. and Pepys, M.B. (1980) Immunohistochemical staining of normal and pathological human tissues with antibody to serum amyloid P component (SAP). *In: Amyloid and Amyloidosis* (Glenner, G.G., Pinho e Costa, P. and de Freitas, F., eds.), Excerpta Medica, Amsterdam, pp. 50-54.
5. Pepys, M.B., Baltz, M.L., Dyck, R.F., de Beer, F.C., Evans, D.J., Feinstein, A., Milstein, C.P., Munn, E.A., Richardson, N., March, J.F., Fletcher, T.C., Davies, A.J.S., Gomer, K., Cohen, A.S., Skinner, M. and Klaus, G.G.B. (1980) Studies of serum amyloid P component (SAP) in man and animals. *In: Amyloid and Amyloidosis* (Glenner, G.G., Pinho e Costa, P. and de Freitas, F., eds.), Excerpta Medica, Amsterdam, pp. 373-383.
6. Skinner, M., Pepys, M.B., Cohen, A.S., Heller, L.M. and Lian, J.B. (1980) Studies of amyloid protein AP. *In: Amyloid and Amyloidosis* (Glenner, G.G., Pinho e Costa, P. and de Freitas, F., eds.), Excerpta Medica, Amsterdam, pp. 384-391.

7. Baltz, M.L., Rogers, S.L., Gomer, K., Davies, A.J.S., Doenhoff, M.J., Klaus, G.G.B. and Pepys, M.B. (1980) Studies of serum amyloid P component (SAP) as an acute phase reactant in mice. *In: Amyloid and Amyloidosis* (Glenner, G.G., Pinho e Costa, P. and de Freitas, F., eds.), Excerpta Medica, Amsterdam, pp. 534-542.
8. Pepys, M.B. (1980) C-reactive protein (CRP) and serum amyloid protein (SAA). *In: Patient Evaluation and Disease Assessment in Rheumatoid Arthritis*. Proceedings of the Fifth ISRA Symposium, Amsterdam, 1979 (Feltkamp, T.E.W., ed.), Staphleus Scientific Publishing Co., Alphen aan de Rijn, pp. 121-126.
9. Pepys, M.B. (1981) Immunoassays of acute phase proteins. *In: Immunoassays for the 80's* (Voller, A., ed.) MTP Press Limited, Lancaster, pp. 341-352.
10. de Beer, F.C., Baltz, M.L., Feinstein, A. and Pepys, M.B. (1983) Selective calcium-dependent binding of fibronectin and C4-binding protein by aggregated serum amyloid P component. *In: Amyloidosis E.A.R.S.* (Tribe, C.R., Bacon, P.A., eds.), John Wright & Sons, Bristol, pp. 80-81.
11. Baltz, M.L., Dyck, R.F. and Pepys, M.B. (1983) Synthesis and turnover of serum amyloid P component in mice. *In: Amyloidosis E.A.R.S.* (Tribe, C.R., Bacon, P.A., eds.), John Wright & Sons, Bristol, pp. 164-166.
12. Pepys, M.B., Breathnach, S.M., de Beer, F.C., Tennent, G., Melrose, S. and Evans, D.J. (1983) Immunohistochemical studies of amyloid P component in normal tissues. *In: Amyloidosis E.A.R.S.* (Tribe, C.R., Bacon, P.A., eds.), John Wright & Sons, Bristol, pp. 187-188.
13. Pepys, M.B., Breathnach, S.M., Black, M.M., Tennent, G., de Beer, F.C., Lanham, J., Zalin, A.M., Tribe, C.R. and Evans, D.J. (1983) Diagnosis and characterisation of amyloid deposits by immunohistochemical staining. *In: Amyloidosis E.A.R.S.* (Tribe, C.R., Bacon, P.A., eds.), John Wright & Sons, Bristol, pp. 189-191.
14. Pepys, M.B. (1983) C-reactive protein and other acute phase reactants. *In: Advances in Immunopharmacology 2* (Hadden, J.W., Chedid, L., Dukor, P., Spreafico, F., Willoughby, D., eds.), Pergamon Press, Oxford, pp. 573-578.
15. Caspi, D., Baltz, M.L., Morgan, S.H., Hart, L.E., Hughes, G.R.V. and Pepys, M.B. (1984) Serum amyloid degrading activity (SADA). Clinical and experimental aspects. *In: Progress in Rheumatology, Vol. II* (Machtey, I., ed.), Rheumatology Service, Hasharon Hospital, Petah-Tiqva, Israel, pp. 31-35.
16. Turnell, W.G., Sarra, R., Glover, I.D., Baum, J.O., Caspi, D., Baltz, M.L. and Pepys, M.B. (1986) Analysis of X-ray scattering by human AA fibrils using secondary structure predictions of human SAA<sub>1</sub>. *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 49-55.

17. Baltz, M.L., Caspi, D., Rowe, I.F., Hind, C.R.K., Evans, D.J. and Pepys, M.B. (1986) Pathogenetic mechanisms and precursor product relationships in murine amyloidosis. *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 101-113.
18. Baltz, M.L., Caspi, D., Hind, C.R.K., Feinstein, A. and Pepys, M.B. (1986) Isolation and characterisation of amyloid enhancing factor (AEF). *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 115-121.
19. Hind, C.R.K., Collins, P.M., Caspi, D., Baltz, M.L. and Pepys, M.B. (1986) Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 233-238.
20. Caspi, D., Baltz, M.L., Feinstein, A., Munn, E.A. and Pepys, M.B. (1986) Does serum degrade amyloid fibrils? Failure to confirm enzymatic degradation of amyloid A fibrils as the basis of the so-called "amyloid degrading activity" of serum. *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 279-284.
21. Hind, C.R.K., Gibson, D.G., Lavender, J.P. and Pepys, M.B. (1986) Non-invasive techniques for demonstrating cardiac involvement in the acquired forms of systemic amyloidosis. *In: Amyloidosis* (Glenner, G.G., ed.), Plenum Publishing Corporation, New York, pp. 617-620.
22. Pepys, M.B. (1986) Pentraxins - perspective from molecules to the bedside. *In: Advances in Inflammation Research, Vol. 10* (Russo-Marie, F., Mencia-Huerta, J.M. and Chignard, M., eds.), Raven Press, New York, pp. 214-217.
23. Pepys, M.B. (1986) Amyloid P component: structure and properties. *In: Amyloidosis* (Marrink, J. and van Rijswijk, M.H., eds.), Martinus Nijhoff Publishers, Dordrecht, pp. 43-49.
24. Turnell, W.G. and Pepys, M.B. (1986) Correlation between sequence variability and structure prediction in AA proteins. *In: Amyloidosis* (Marrink, J. and van Rijswijk, M.H., eds.), Martinus Nijhoff Publishers, Dordrecht, pp. 127-133.
25. Perkins, S.J. and Pepys, M.B. (1986) X-ray and neutron scattering studies on CRP and SAP. *In: Protides of the Biological Fluids, Vol. 34* (Peeters, H., ed.), Pergamon Press, Oxford, pp. 323-326.
26. Turnell, W., Sarra, R., Baum, J.O. and Pepys, M.B. (1986) Modelling APOSAA/phospholipid interactions. *In: Protides of the Biological Fluids, Vol. 34* (Peeters, H., ed.), Pergamon Press, Oxford, pp. 363-366.

27. Oliva, G., O'Hara, B.P., Wood, S., Pepys, M.B. and Blundell, T. (1986) Preliminary crystallographic studies of serum amyloid P component (SAP). *In: Protides of the Biological Fluids, Vol. 34* (Peeters, H., ed.), Pergamon Press, Oxford, pp. 371-374.
28. White, H.E., O'Hara, B.P., Oliva, G., Blundell, T.L., Pepys, M.B. and Wood, S.P. (1989) The three dimensional structure of SAP. *In: Acute Phase Proteins in the Acute Phase Response* (Pepys, M.B., ed.), Springer-Verlag, London, pp.123-136.
29. Hawkins, P.N. and Pepys, M.B. (1989) Serum amyloid P component: a specific molecular targeting vehicle in amyloidosis. *In: Acute Phase Proteins in the Acute Phase Response* (Pepys, M.B., ed.), Springer-Verlag, London, pp.187-206.
30. Hawkins, P.N., Wootton, R. and Pepys, M.B. (1991) Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 254-257.
31. Pepys, M.B., Hawkins, P.N., Tennent, G.A., Nelson, S.R., Amatayakul-Chantler, S., Dwek, R.A., Rademacher, T.W. and Butler, P.J.G. (1991) Structural and functional studies of serum amyloid P component. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 258-259.
32. Hawkins, P.N. and Pepys, M.B. (1991) A primed state exists *in vivo* following regression of murine AA amyloidosis. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 264-267.
33. Nelson, S.R., Lyon, M., Gallagher, J.T., Johnson, E.A. and Pepys, M.B. (1991) Isolation and characterisation of the integral glycosaminoglycan constituents of human AA and AL amyloid fibrils. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 338-341.
34. Pepys, M.B. (1991) New images of clinical amyloidosis. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 765-770.

35. Hawkins, P.N., Lavender, J.P. and Pepys, M.B. (1991) Scintigraphic imaging of amyloidosis with <sup>123</sup>iodine serum amyloid P component. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 771-774.
36. Hawkins, P.N., Feest, T.G. and Pepys, M.B. (1991) Imaging hereditary amyloidosis of Ostertag. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 789-792.
37. Sipe, J.D., de Beer, F.C., Pepys, M., Husebekk, A., Skogen, B., Kisilevsky, R., Selkoe, D., Buxbaum, J., Linke, R.P. and Gertz, M.A. (1991) Report of special session on bioassays and standardization of amyloid proteins and precursors. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 883-889.
38. Nelson, S.R., Tennent, G.A., Sethi, D., Gower, P.E., Ballardie, F.W., Amatayakul-Chantler, S. and Pepys, M.B. (1991) Serum amyloid P component in chronic renal failure and dialysis. *In: Amyloid and Amyloidosis 1990* (Natvig, J.B., Forre, O., Husby, G., Husebekk, A., Skogen, B., Sletten, K., Westermark, P., eds.), Kluwer Academic Publishers, Dordrecht, pp. 902-905.
39. Chavatte, P.M., Pepys, M.B., Roberts, B., Ousey, J.C., McGladdery, A.J. and Rossdale, P.D. (1992) Measurement of serum amyloid A protein (SAA) as an aid to differential diagnosis of infection in newborn foals. *In: Equine Infectious Diseases, VI* (Plowright, W., Rossdale, P.D. and Wade, J.F. eds.), R & W Publications (Newmarket) Limited, pp. 33-38.
40. Hutton, T., McDowall, M.A., Pepys, M.B., Noble, G. and Gallimore, R. (1992) The analysis of pentraxin proteins by electrospray mass spectrometry. *Proc. 40th ASMS Conference on Mass Spectrometry and Allied Topics*, Washington, DC, May 31-June 5, 1992.
41. Pepys, M.B., Noble, G., Gallimore, J.R., Amatayakul-Chantler, S., Rademacher, T.W., Dwek, R.A., Hutton, T. and Lowes, S. (1993) ESMS of human serum amyloid P component: confirmation of the structure and analysis of the role of the glycan. *Proc. 41st ASMS Conference on Mass Spectrometry and Allied Topics*, San Francisco, California, May 30-June 4, 1993.
42. Tennent, G.A. and Pepys, M.B. (1994) Glycobiology of the pentraxins. *Biochem. Soc. Trans.*, **22**: 74-79.

43. Vigushin, D.M., Pepys, M.B. and Hawkins, P.N. (1994) Rapid regression of AA amyloidosis following surgery for Castleman's disease. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 48-50.
44. Wilkins, J., Gallimore, J.R., Tennent, G.A., Moore, E.G. and Pepys, M.B. (1994) Rapid automated enzyme immunoassay for serum amyloid A protein on the Abbott IM<sub>x</sub><sup>TM</sup> instrument. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 143-145.
45. Pepys, M.B., Amatayakul-Chantler, S., Hutton, T., Noble, G.E., Nelson, S.R., Hutchinson, W.L., Glass, D., Hawkins, P.N., Rademacher, T.W. and Dwek, R.A. (1994) Glycobiology of human serum amyloid P component. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 177-179.
46. Hutchinson, W.L., Noble, G.E., Hawkins, P.N. and Pepys, M.B. (1994) Serum amyloid P component is taken up and catabolised in hepatocytes. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 180-182.
47. Pepys, M.B., White, H.E., Emsley, J., Oliva, G.O., O'Hara, B.P., Wood, S.P., Tickle, I.J. and Blundell, T.L. (1994) Three-dimensional structure of human SAP at 2.0Å. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 183-185.
48. Hawkins, P.N., Vigushin, D.M., Richardson, S., Seymour, A. and Pepys, M.B. (1994) Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 209-211.
49. Vigushin, D.M., Clesham, G., Hawkins, P.N., Nihoyannopoulos, P., Joshi, J., Oakley, C. and Pepys, M.B. (1994) Echocardiography in systemic AL amyloidosis. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 268-270.
50. Vigushin, D.M., Hawkins, P.N., Sawle, G., Lees, A.J., Hsuan, J.J., Totty, N.F., Powell, M., Vulliamy, T. and Pepys, M.B. (1994) AL $\kappa$  amyloid in a solitary extradural lymphoma. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 271-273.

51. Vigushin, D.M., Vulliamy, T., Kaeba, J.S., Hawkins, P.N., Luzzatto, L. and Pepys, M.B. (1994) Immunoglobulin gene rearrangement analysis in AL amyloidosis. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 287-289.
52. Pepys, M.B., Booth, D.R., Vigushin, D.M., Tennent, G.A., Soutar, A.K., Hsuan, J.J., Totty, N.F., Nguyen, O., Blake, C.C.F., Terry, C.J., Feest, T.G., Zalin, A.M. and Pepys, M.B. (1994) Mutations in the human lysozyme gene cause hereditary systemic amyloidosis (Ostertag type). *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, p. 437.
53. Booth, D.R., Soutar, A.K., Hawkins, P.N., Reilly, M., Harding, A. and Pepys, M.B. (1994) Three new amyloidogenic transthyretin gene mutations: advantages of direct sequencing. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 456-458.
54. Vigushin, D.M., Hawkins, P.N. and Pepys, M.B. (1994) Clinical phenotypes in familial amyloid polyneuropathy associated with new transthyretin variants Val47 and Pro52. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 483-485.
55. Pepys, M.B. (1994) Recent developments in clinical amyloidosis. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 636-637.
56. Hawkins, P.N., Vigushin, D.M., Richardson, S., Seymour, A., Holmgren, G., Steen, L., Woo, P., Hall, A., Peters, A.M. and Pepys, M.B. (1994) Natural history and regression of amyloidosis. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 638-641.
57. Hawkins, P.N., Hall, M., Hall, R., Penny, L., Henderson, A., Yacoub, M., Mitchell, A. and Pepys, M.B. (1994) Regression of AL amyloidosis and prolonged survival following cardiac transplantation and chemotherapy. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gauldie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 657-659.



58. Hutchinson, W.L., Mather, S.J., Staltieri, M., Noble, G.E., Vigushin, D.M., Tan, S.Y., Seymour, A., Pepys, M.B. and Hawkins, P.N. (1994) Scintigraphic imaging of amyloid deposits with  $^{99m}\text{Tc}$ -labelled serum amyloid P component. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gaudie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 682-684.
59. Vigushin, D.M., Pepys, M.B. and Hawkins, P.N. (1994) Comparison of histology with SAP scintigraphy for evaluation of amyloidosis. *In: Amyloid and Amyloidosis 1993* (Kisilevsky, R., Benson, M.D., Frangione, B., Gaudie, J., Muckle, T.J. and Young, I.D., eds.), Parthenon Publishing, Pearl River, New York, pp. 685-687.
60. Pepys, M.B., Tennent, G.A., Booth, D.R., Bellotti, V., Lovat, L.B., Tan, S.Y., Persey, M.R., Hutchinson, W.L., Booth, S.E., Madhoo, S., Soutar, A.K., Hawkins, P.N., Van Zyl-Smit, R., Campistol, J.M., Fraser, P.E., Radford, S.E., Robinson, C.V., Sunde, M., Serpell, L.C. and Blake, C.C.F. (1996) Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. *In: The nature and origin of amyloid fibrils* (Bock, G.R. and Goode, J.A., eds.), Wiley, Chichester (Ciba Foundation Symposium 199), pp. 73-89.
61. Pepys, M.B. (1999) Serum amyloid P component. Structure, function and role in amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 6-10.
62. Booth, D.R., Gallimore, J.R., Hutchinson, W.L., Hohenester, E., Thompson, D., Wood, S. and Pepys, M.B. (1999) Analysis of autoaggregation and ligand binding sites of serum amyloid P component by *in vitro* mutagenesis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 23-25.
63. Lovat, L.B., Hohenester, E., Westermark, P., Wood, S.P. and Pepys, M.B. (1999) Nature and specificity of amyloid fibril binding by serum amyloid P component. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 29-31.
64. Hutchinson, W.L., Hohenester, E., Perkins, S.J., Herbert, J. and Pepys, M.B. (1999) Human serum amyloid P component in whole serum is pentameric and is not complexed with other proteins. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 32-34.
65. Gillmore, J.D., Apperley, J.F., Craddock, C., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1999) High-dose melphalan and stem cell rescue for AL amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 102-104.

66. Hawkins, P.N., Aprile, C., Capri, G., Vigano, L., Munzone, E., Gianni, L., Pepys, M.B. and Merlini, G. (1999) Scintigraphic imaging and turnover studies with  $^{131}\text{I}$ -serum amyloid P component (SAP) in systemic amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 139-141.
67. Gillmore, J.D., Persey, M.R., Lovat, L.B., Madhoo, S., Pepys, M.B. and Hawkins, P.N. (1999) Serum amyloid P component scintigraphy in AL amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 148-150.
68. Tennent, G.A., Cafferty, K.D., Pepys, M.B. and Hawkins, P.N. (1999) Congo red overlay immunohistochemistry aids classification of amyloid deposits. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 160-162.
69. Stangou, A.J., Heaton, N.D., Rela, M., Jewitt, D., Mathias, C.J., O'Grady, J., Williams, R.S., Pepys, M.B. and Hawkins, P.N. (1999) Orthotopic liver transplantation for familial amyloid polyneuropathy: the UK experience. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 238-240.
70. Stangou, A.J., Booth, D.R., Heaton, N.D., Rela, M., Monaghan, M., Nihoyannopoulos, P., O'Grady, J., Williams, R., Pepys, M.B. and Hawkins, P.N. (1999) Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 330-332.
71. Hawkins, P.N., Rydh, A., Danielsson, Å., Cajander, S., Hietala, S.-O., Riklund Åhlström, K., Pepys, M.B. and Suhr, O. (1999) SAP scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 333-335.
72. Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Williams, R.S., Harrison, P., Pepys, M.B. and Hawkins, P.N. (1999) Curative hepatorenal transplantation for systemic amyloidosis associated with fibrinogen  $\alpha$ -chain Glu526Val in an English family. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 336-338.
73. Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. (1999) SAA<sub>1</sub> alleles as risk factors in AA amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 369-371.

74. Hawkins, P.N., Herbert, J., McBride, A., Hutchinson, W.L. and Pepys, M.B. (1999) Natural history of experimental murine AA amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 387-389.
75. Gillmore, J.D., Lovat, L.B., Persey, M.R., Madhoo, S., Gallimore, J.R., Pepys, M.B. and Hawkins, P.N. (1999) Cumulative SAA production and outcome of AA amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 402-404.
76. Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N. and Pepys, M.B. (1999) Alpha-1 antiprotease alleles as risk factors in AA amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 414-416.
77. Booth, D.R., Gillmore, J.D., Pepys, M.B. and Hawkins, P.N. (1999) Transthyretin mutations in patients with apparent senile cardiac amyloidosis. *In: Amyloid and Amyloidosis 1998* (Kyle, R.A. and Gertz, M.A. eds.), Parthenon Publishing, Pearl River, New York, pp. 554-555.
78. Lachmann, H.J., Goodman, H.J.B., Gallimore, J., Gilbertson, J.A., Joshi, J., Pepys, M.B. and Hawkins, P.N. (2005) Characteristic and clinical outcome of 340 patients with systemic AA amyloidosis. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, pp. 173-175.
79. Stangou, A.J., Heaton, N.D., Rela, M., O'Grady, J., Mathias, C.J., Goodman, H.J.B., Lachmann, H.J., Bybee, A., Rowzcenio, D., Joshi, J., Williams, R.S., Pepys, M.B. and Hawkins, P.N. (2005) Liver transplantation in ATTR Met30 and other variants: time to shift the paradigm? *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, pp. 306-308.
80. Stangou, A.J., Lachmann, H.J., Goodman, H.J.B., Bybee, A., Rowzcenio, D., Tennent, G., Brennan, S.O., O'Grady, J.G., Heaton, N.D., Rela, M., Pepys, M.B. and Hawkins, P.N. (2005) Fibrinogen A  $\alpha$ -chain amyloidosis: clinical features and outcome after hepatorenal or solitary kidney transplantation. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, pp. 312-314.
81. Bybee, A., Kang, H.G., Ha, I.S., Park, M.S., Cheong, H.I., Choi, Y., Gilbertson, J.A., Pepys, M.B. and Hawkins, P.N. (2005) A novel complex indel mutation in the fibrinogen A $\alpha$  chain gene in an Asian child with systemic amyloidosis. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, p. 315.

82. Hawkins, P.N., Bybee, A., Goodman, H.J.B., Lachmann, H.J., Rowczenio, D., Gilbertson, J.A., O'Grady, J., Heaton, N., Stangou, A. and Pepys, M.B. (2005) Phenotype, genotype and outcome in hereditary apoAI amyloidosis. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, p. 316.
83. Bybee, A., Hollenbeck, M., Debusmann, E.R., Gopaul, D., Gilbertson, J.A., Lachmann, H.J., Pepys, M.B. and Hawkins, P.N. (2005) Hereditary renal amyloidosis in a German family associated with fibrinogen A  $\alpha$  chain Glu540Val. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, p. 367.
84. Pepys, M.B. (2005) Serum amyloid P component as a therapeutic target in amyloidosis. *In: Amyloid and Amyloidosis* (Grateau, G., Kyle, R.A. and Skinner, M., eds.), CRC Press, Boca Raton, Florida, pp. 488-490.

#### **IV. PATENT**

1. Therapeutic and Diagnostic Agents for Amyloidosis. Freemedic PLC, M.B. Pepys and T.L. Blundell. US Patent No. 6,126,918 issued 3 October 2000.